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ABSTRACT
CARDIAC ABNORMALITIES AFTER TRANSAORTIC CONSTRICTION ARE
WORSENED BY CHANGING GLUCOSE METABOLISM AND BENEFITED BY
REPAIR OF MITOCHONDRIAL DNA
J ianxun Wang

April 1, 2011
Heart failure is a leading cause of morbidity and mortality in the USA. During the
development of heart failure, many cardiac parameters change at the same time including
fuel metabolism, oxidative stress and mitochondrial function. Each of these changes
occurs in the context of multiple other abnormalities in the failing heart. This complexity
makes it difficult to discern the importance of each of these parameters. In this
dissertation changes in glucose metabolism and mitochondrial DNA repair have been
targeted separately and specifically in the heart to test their roles in heart failure
independently.

Abnormal glucose metabolism is always found in heart failure patients. During
heart failure there is a significant increase in cardiac glycolysis. On the other hand,
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diabetic patients, who are at increased risk of heart failure show the opposite change in
glucose metabolism, their level of glycolysis goes down. In these studies separate lines
of transgenic mice with increased or decreased glycolysis were used to test if these
changes in glucose metabolism altered the development of heart failure induced by
pressure overload after transaortic constriction (TAC) surgery. Cardiac glycolysis was
targeted by 2 transgenes that alter the level of fructose-2 ,6-P2 (F-2,6-P2)' which activates
phosphofrucokinase. The Mb trans gene reduces F-2,6-P 2 and slows glycolysis. The Mk
transgene increases F-2,6-P2 and speeds glycolysis. Mb and Mk transgenic hearts had
normal structure and function after sham surgery but they were both much more
susceptible to damage from TAC surgery than non-transgenic mice. In both lines of mice
TAC produced more fibrosis , more collagen expression, greater hypertrophy, lower
fractional shortening, higher lung weight and reduced energy reserves. Mb mice also
showed more oxidative stress. These results indicate loss of cardiac flexibility to control
glucose metabolism is detrimental to the heart.

Cardiac failure is associated with increased levels of oxidized mitochondrial
DNA (mtDNA). It is not known if oxidized mtDNA contributes to cardiac dysfunction.
To test if protection of mtDNA can reduce cardiac injury, we produced transgenic mice
with cardiomyocyte-specific overexpression of the mitochondrial form of the DNA repair
enzyme 8-oxoguanine DNA glycosylase

1 (OGG 1).

OGG 1 transgenic mice

demonstrated significantly lower cardiac mitochondrial levels of the DNA guanine
oxidation product 7,8-dihydro-8-oxoguanine (8-oxo-dG).

This was true under basal

conditions, after Doxorubicin administration or after T AC. OGG 1 mice were tested for

v

protection from TAC surgery. Compared to FVB-TAC mice, hearts from OGG 1-TAC
mice had lower levels of ~-MHC mRNA but they did not display significant differences
in hypertrophy or function.

The principle benefit of OGG 1 overexpression was a

significant decrease in T AC induced cardiac fibrosis, indicated by reduced Sirius Red
staining and by significantly decreased induction of collagen 1 and 3 mRNA expression.
These results provide a new model to assess the cardiac effects of mtDNA damage and
demonstrate that oxidation of mtDNA contributes to cardiac pathology.
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INTRODUCTION

Heart failure is the consequence of multiple pathophysiological adaptations and
alterations, leading to left ventricular (LV) hypertrophy, dilation and dysfunction. Heart
failure can develop as a result of the following models: in the cardiorenal model, heart
failure is regarded as a problem of excessive salt and water retention, thus requiring the
use of diuretics drugs. In the hemodynamic model, heart failure derives from
abnormalities of pumping capacity and excessive peripheral vasoconstriction which can
be controlled with the use of inotropic drugs and vasodilators. In the neurohormonal
model, heart failure progresses as a result of increased production of biologically active
molecules, such as norepinephrine and angiotensin 2, which are capable of exerting
deleterious effects on the heart, independent of the hemodynamic status; for this
condition, drugs such as beta adrenergic blockers, angiotensin-converting enzyme
inhibitors (ACEI) and angiotensin 2 antagonists are used. Although good therapeutic
effects have been achieved using beta blockers, ACEI and angiotensin 2 antagonists, the
mortality rate from heart failure is still very high. Therefore, new targets for treating heart
failure are urgently needed. One emerging target for heart failure therapy involves
changes in cardiac metabolism (65).
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Under normal conditions, fatty acids provide 70% of the energy for the heart
while glucose and lactate provide 30% of the energy (24, 68 , 84) . Cardiac glucose uptake
is driven by a glucose gradient and is dependent on the density of sarcolemmal glucose
transporters (Gluts) such as Giutl and Glut4. Giutl has a more continuous sarcolemmal
location and facilitates basal glucose uptake more so than Glut4. However, Glut4 is the
dominant transporter in the adult heart, with a majority of this transporter located in an
intracellular pool under basal conditions; upon activation by insulin, Glut4 translocates to
the cell membrane to transport glucose (49, 58, 79). Entry of glucose into the
cardiomyocyte begins glycolysis . Glycolysis is controlled by a series of enzymes
includings hexokinase, phospho fructose kinase-I (PFK-1), phospho fructose kinase-2
(PFK-2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase (
PK) with the end result being the production of pyruvate (16). After glycolysis, pyruvate
enters mitochondria for glucose oxidation. The importance of glycolysis is much more
than just the metabolism of glucose. A TP derived from glycolysis seems to have a
preferential role in maintaining normal conductance of calcium, potassium and sodium
ions in the cell membrane (20, 92, 110). Also intermediate products of glycolysis
provide the substrates for the synthesis of glycogen, NADPH and other cellular
molecules.

The alternate source of cardiac energy, fatty acids (FA), are transported to the
heart by way of three FA transport proteins: CD36, FA transport protein (FATP) and FA
binding protein plasma membrane (FABPpm) (59). Once the FA enters cardiomyocytes,
it is esterfied by acyl-CoA synthase (ACS), and the resulting fatty acyl-CoA is
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transported into mitochondria for oxidation, or stored as triglycerides (Tg). In normal
heart, there is a balance between lipogenesis and lipolysis to control intracellular Tg level
(84). If the FA level is much greater than the cellular oxidative capacity, Tg can
accumulate and lipotoxictiy follows . There is an interaction between glucose metabolism
and fatty acid metabolism, called the Randle cycle (34). Increased fatty acid utilization
can inhibit glucose oxidation and glycolysis by decreasing pyruvate dehydrogenase
complex (PDC) activity and inhibiting PFK-1 activity and glucose uptake. Conversely,
hyperglycemia can reduce fatty acid oxidation, probably by increasing the intracellular
level of malconyl-CoA to inhibit carnitine palmitoyltransferase I (CPT-I) activity.

Hallmarks for hypertrophied and failing hearts are changes in substrate utilization
and energy metabolism. Consistent findings in most forms of heart failure are increased
glucose consumption and decreased fatty acid oxidation (38 , 101). In contrast, diabetic
hearts exhibit the opposite metabolic changes, glucose consumption is decreased and
fatty acid oxidation is increased. These diabetic effects on cardiac metabolism are due to
insulin resistance in type 2 diabetes and insulin deficiency in type 1 diabetes (22).
Notably, diabetes is also an independent risk factor for ultimate development of heart
failure (104). Therefore increased or decreased glucose metabolism can playa role in
heart failure under different pathological conditions. It is also known that heart failure
induced by any cause causes higher levels of oxidative stress (5 , 44, 72) in large part due
to increased production of mitochondrial reactive oxygen species (ROS). These higher
levels ofROS may oxidize mitochondrial DNA (mtDNA) (36). Oxidized mtDNA may
further damage mitochondrial function, increase ROS production and worsen heart
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failure syndrome in a vicious cycle. Therefore oxidation of mtDNA may playa very
important role in the development of heart failure.

Because abnormal cardiac fuel metabolism is closely associated with the
progression of heart failure, and because abnormal cardiac metabolism induces more
mitochondrial ROS resulting in mtDNA oxidation, we carried out three studies on the
pathogenesis of heart failure induced by pressure overload: We tested the hypothesis that
reduced glycolysis exacerbates heart failure. We tested the converse hypothesis that
increased glycolysis protects from heart failure. Lastly we tested the hypothesis that
reduced mtDNA oxidative damage also protect from heart failure. This dissertation is
divided into three chapters which correspond to these three hypotheses.

Chapter I: Decreased glycolysis increases susceptibility to cardiac hypertrophy
and heart failure

Chapter II: Increased glycolysis increases susceptibility to cardiac hypertrophy
and heart failure

Chapter Ill: Cardiac overexpression of mitochondrial 8-oxoguanine DNA
glycosylase 1 protects against cardiac fibrosis in heart failure
Chapter IV: Overview and relevance of dissertation studies
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CHAPTER I
DECREASED GLYCOLYSIS INCREASES SUSCEPTIBILITY TO CARDIAC
HYPERTROPHY AND HEART FAILURE
INTRODUCTION

Cardiac glucose and fat metabolism are tightly and inversely regulated, as
controlled by the Randle cycle (67). Under normal circumstances glucose accounts for
only a small portion of cardiac energy supply, but in the failing heart, glucose
consumption becomes more important. This has been appreciated for over 40 years
since Bishop and Altshud reported (9) that glycolytic metabolism is increased in cardiac
hypertrophy and congestive heart failure. However, it is still uncertain whether the
elevation of cardiac glucose metabolism is an adaptive response of the failing heart or
simply one more example of the prominent reversion to fetal gene expression that occurs
during congestive heart failure (CHF) (87).

Most efforts to inhibit cardiac glucose metabolism have utilized knockdown of
one of the cardiac glucose transporters (18, 40) but control of glycolysis is actually
shared by several reactions (43). One of these reactions is carried out by 6phosphofiucto-l-kinase (PFKl) (33 , 70). Unlike glucose transport where there are 2
transporters that can compensate for one another (1), there is only a single PFKl enzyme.
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PFK1 activity is tightly controlled. The most important positive regulator ofPFK1 is
fructose-2, 6-bisphosphate (F-2, 6-P 2), which is increased several fold in hypertrophied
heart (66). We have previously described a transgenic mouse designated Mb (19) which
has reduced cardiac levels ofF-2,6-P2 and a subsequent reduction in glycolytic rate.

To test whether prevention of cardiac hypertrophy- induced elevation ofF-2,6-P 2
and glycolysis changes the progression of cardiac failure, Mb transgenic mice were
subject to pressure overload by transaortic constriction (TAC) for 13 weeks. TAC mimics
human aortic stenosis with development of pressure overload induced left ventricular
hypertrophy. Heart failure, reductive status and oxidative stress were exacerbated in Mb
mice, indicating that up regulation of glycolysis helps protect the heart from chronic
pressure overload.

MATERIALS AND METHODS
Animals

Mb transgenic mice (19) and control mice were maintained on the background
FVB . Male mice between ages 90- 100 days were used for experiments. All animal
procedures conformed to the National Institutes of Health Guide for the Care and Use of

Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and were approved by the
United State Department of Agriculture-certified University of Louisivlle animal care and
use committee.

Transaortic constriction (T AC) surgery
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T AC surgery was performed by a modification of a previously published
technique (6). Mice were anesthetized with avertin (O.4g/kg), maintained on a 37°C pad
and ventilated with 100% oxygen. An incision at the left second intercostal space was
made to open the chest. A chest retractor was applied to facilitate the view. The thymus
was pulled away and transverse aorta was dissected from surrounding tissues. A 6-0 silk
suture was passed around the transverse aorta and tightened against a 26G needle. The
needle was immediately removed to provide a lumen with a stenotic aorta. Lungs were
inflated and the chest cavity, muscles and skin were closed layer by layer with 6-0 silk
sutures. The whole procedure lasted 20-30 min. After surgery, mice were warmed with a
heating lamp and received an intraperitoneal injection of O.Sml of saline at 37°C. For 48
h mice were given subcutaneous injections ofbuprenorphine, O.lmglkg every 12 h. Sham
mice were the same as T AC animals except that banding of the transverse aorta was
omitted.

Echocardiographic Assessment of Cardiac Function
Transthoracic echocardiography of the left ventricle was performed using a ISMHz linear array transducer (lSL8) interfaced with a Sequoia CS12 system (Acuson) as
previously described (109). Mice were anesthetized with 2% isoflurane, maintained under
anesthesia with 1.2S% isoflurane, and examined. Ventricular parameters were measured
in M-mode with a sweep speed 200 mmls. The echocardiograms were captured from
short-axis views of the left ventricle (LV) at the midpapillary level. LV percent fractional
shortening

(L V%FS)

was

calculated

according
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to

the

following

equation:

LV%FS=[(LVEDD-LVESD)/LVEDD]x100.

All

data

were

calculated

from

10

independent cardiac cycles per experiment.

Quantitative Real Time Polymerase Chain Reaction (RT-PCR)
Cardiac RNA was extracted with Trizol reagent. The total RNA was transcribed
to eDNA with Superscript II enzyme and random oligonucleotide primers (Invitrogen).
The primers, probes and reaction buffer for RT-PCR were purchased from AB (Applied
Biosystem) including a-MHC ( alpha myosin heavy chain, Mm01313844_mH),

~-MHC(

beta myosin heavy chain, Mm00600555_m1), ANP (Atrial natriuretic peptide ,
Mm01255748_g1), BNP (Brain natriuretic peptide, Mm01255770_g1), procollagen
1a1(Mm01302043_g1),
(Hs99999901 _s1)

procollagen

3a1(Mm01254476_m1),

18s

RNA

and 2xMaster buffer. RT-PCR was performed on an AB 7300

thermocycler with 35 cycles, each cycle consisted of 95 °C for 15 seconds, 55°C for 15
seconds and 75 °C for 30 seconds. 18sRNA was used as endogenous control. Relative
abundance of transcripts was determined by the delta-delta CT method.

Histological experiments
Cryostat sections (5 /lm) were fixed in 10% formalin for 15min and washed three
times with PBS. The cryostat slides were incubated with a saturated solution of picric
acid containing 0.1% Sirius red for staining collagen and 0.1 % fast green for staining
noncollagen proteins. Staining was performed in the dark for 2 hours. The slides were
rinsed with distilled water, dehydrated with

al~ohol ,

and mounted with permount. The

sections were visualized and photographed by a blinded observer. Interstitial fibrosis was
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scored by a blinded observer against reference images using a scale of 1 to 4 based on the
severity of fibrosis with scores of 1 for low; 2 for mild; 3 for moderate and 4 for severe.

Western blots
Immunobloting was performed as previously described (l 07) with modification.
In brief, frozen cardiac tissue was homogenized with lysis buffer containing 50mmoi/L
Tris-HCI (pH7.5), 5mmoliL EDTA, lOmmoliL EGTA, I x cocktail protease inhibitor, l x
alkaline phosphatase inhibitor and 1xacid phophatase inhibitor, 50 ug/ml
phenylmenthysulfonyl fluoride and 1.23mg/ml Chaps (3-[ (3-Cholamidopropyl )
dimethylammonio]-l-propanesulfonate ). Extracts were centrifuged at 12000rpm at 4 DC
for 15 minutes. The protein concentration was determined by Lowry method (Pierce).
Ten ug of the sample proteins was mixed with loading buffer ( 40mmoliL Tris-HCI, pH
6.8, 1% SDS, 50mmoliL DTT, 7.5% glycerol and 0.003% bromophenol blue) and heated
at 95 DC for 5 minutes, and subjected to electrophoresis on a gradient gel ( 4% to 12%,
Invitrogen) at 120V. After electrophoresis, the protein was transferred to a PVDF
membrane in a transfer buffer (Invitrogen). The PVDF membrane was rinsed briefly in
TBS buffer containing 50mM Tris, 137 mM NaCI, pH 7.5 and blocked in buffer (5%
milk with 0.5% BSA in TBST buffer (TBS buffer containing 0.1 % tween 20) at room
temperature for 1 hour. The membrane was then incubated with rabbit anti 4-hydroxy-2noneal (4HNE) antibody at 1:3000 dilution(Abcam) at 4 DC over night, followed by
washing three times. The secondary antibody was incubated with the membrane for
another one hour at room temperature. Finally the antigen-antibody complexes were
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visualized by use of an enhanced chemiluniescence ( ECL, GE healthcare ) kit. AntiGAPDH (Abcam) was used for normalization of signals for different samples.

Metabolites measurement

For the assay oflactate, pyruvate, ATP and phosphocreatine, freeze clamped
hearts were powdered in liquid nitrogen and weighed. Powered samples were
homogenized in 1M ice cold perchloric acid and centrifuged. Supernatants were
neutralized with 2M KHC0 3 .The supernatant from neutralized extracts was used for the
estimation of these metabolites by the flurometric method (55).

For assay ofF-2,6-P 2, freeze clamped heart tissue was homogenized with 10-20
volumes of 50mM NaOH and kept at 80°C for 5min. The extract was cooled and
neutralized on ice by adding 1M acetic acid with 20mM HEPES . After centrifugation at
8000g for 10min, the supernatant was collected for F-2,6-P2 analysis by the PFK-l
activation method (19, 108).

Pyridine nucleotides were measured using a spectrophotometric enzymatic
cycling method (8, 116) for both the oxidized and reduced forms ofNADP(H) and
NAD(H) with modification. Briefly, freeze clamped heart tissue was homogenized with
30 volumes of cold 40mM NaOH containing 0.5mM cysteine buffer for 30 seconds.
After centrifuging at 10000rpm for 15min, the supernatant was divided into two parts.
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One part was heated at 60°C for 20 min to destroy all NAD(P) for assay ofNADH or
NADPH, the other part was kept on ice for assay of total NADP(H) or NAD(H) . The
difference between heated and unheated reactions yields NADP+ or NAD+ content. For
NAD(H) assay, the buffer containing IOOmM Tris-HCI, pH 8.0, 2mM PES (phenazine
ethosulfate), O.SmM MTT ( 3-(4,S-dimethylthiazolyl-2)-2,S-diphenyltetrazolium
bromide), 0.2mg/ml ADH (alcohol dehydrogenase) and 600 mM alcohol was used. For
assay ofNADP(H) buffer containing IOOmM Tris-HCI pH 8.0, SmM EDTA, 2mM PES,
O.SmM MTT, 1.3U/ml G6PDH (glucose-6-phosphate dehydrogenase) and 1.0mM G-6-P
( glucose-6-phosphate) was used. The reaction mixtures were kept at room temperature
for ISmin, then, read by spectrophotometer at S60nm.

Statistical analysis
Statistical comparisons were performed by two-way ANOV A using Sigma Stat
software with sham or TAC surgery as one factor and transgenic or non-transgenic as the
other factor. The accepted level of significance was O.OS.

RESULTS

Cardiac structural and functional changes after TAC surgery

TAC surgery was performed to assess whether Mb hearts were more sensitive than
FVB hearts to pressure overload stress. Thirteen weeks after surgery, both groups ofTAC
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hearts were significantly enlarged compared to sham hearts (Figure 1). There was no
significant difference between Mb-sham and FVB sham hearts but Mb-T AC hearts were
significantly larger than FVB-TAC hearts (p<0.05). Heart weight to tibia length ratio
increased by 49% in FVB mice and by 70% in Mb mice, as a function of TAC versus
sham surgery. The results indicate that decreased glycolysis in Mb mice promotes
greater hypertrophy in response to pressure overload.

Echocardiography was used to assess the cardiac structural and functional
changes (Table 1). Left ventricular end diastolic diameter (LVEDD) and left ventricular
end systolic diameter (LVESD) were significantly increased in Mb-TAC and FVB-T AC
compared to the corresponding sham hearts. Both L VEDD and LVESD were greater in
Mb TAC compared to FVB TAC hearts. Fractional shortening (FS) was reduced by TAC
and to a greater extent in Mb-TAC hearts than in FVB-TAC hearts. Thus, in addition to
hypertrophy, the Mb trans gene worsened the functional response to TAC surgery.

Semiquantative analysis showed that fibrosis was significantly increased 13
weeks after TAC surgery (Figures 2A and B, p<0.05). This analysis also showed that
interstitial fibrosis staining was greater in Mb-TAC mice compared to FVB-TAC (
p<0.05). The staining analysis was supported by quantitative RT-PCR assays of cardiac
collagen 1a mRNA expression (Figures 2C). Compared to FVB-TAC mice, expression of
collagen 1a mRNA was 4 fold higher in Mb-TAC mice. Collagen 3a mRNA also
increased, but without significant difference between FVB-TAC and Mb-TAC mice.
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An increase in the ratio of lung weight to tibia length is a feature of heart failure .
Thirteen weeks after TAC surgery, there was no an increase of this parameter in FVB
mice. In contrast, Mb mice showed a significant elevation of lung weight to tibia length
ratio (Figure 3), which was 37% higher than the ratio in FVB-TAC mice (p<O.05). This
reinforces the impression that the Mb trans gene makes the heart more susceptible to
pressure overload.

Hypertrophic biomarkers BNP, ANP,

~-MHC

and a-MHC mRNAs were

investigated by quantitative RT-PCR (Figure 4). Expression of each of these biomarkers
was significantly changed by TAC surgery. The effect ofTAC on BNP, ANP and

~

MHC mRNA content was not significantly different in Mb and FVB mice, whereas
expression ofa-MHC mRNA was significantly lower in Mb-TAC mice compared to
FVB-T AC mice.

TAC induced changes in energy reserves, F-2,6-P 2, lactate and pyruvate and in FVB
and Mb hearts

In heart failure the ratio of phosphocreatine (PCr) to ATP is a prognostic indicator
of survival (69). ATP and PCr were reduced by TAC surgery in both groups of mice
(Figure 5). The ratio of PCr to ATP was significantly lower in Mb-TAC hearts compared
to FVB-TAC hearts ; suggestive of more severely impaired cardiac energy reserves in
Mb-TAC mice.
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Mb transgenic mice were created to reduce glycolysis by reducing the level ofF2,6-P2 (19). The reduction in F-2,6-P 2 was confirmed in hearts from Mb-sham mice
(Figure 6A). TAC surgery increased cardiac F-2,6-P2 in both FVB and Mb mice but the
F-2,6-P2 levels in Mb-TAC hearts were still significantly lower than in FVB-TAC hearts.
Figures 6B and C show cardiac content for the end products of glycolysis, lactate and
pyruvate. In Mb- sham hearts lactate was lower but pyruvate was higher than in FVBsham hearts. This yields a lower lactate to pyruvate ratio (Figure 6D) which is an
indicator of a higher cytosolic reductive status (61) in Mb-sham hearts. After TAC
surgery lactate declined significantly in FVB hearts and pyruvate declined significantly in
Mb hearts. As a result, after TAC there was no longer a difference in lactate to pyruvate
ratio.

The changes of redox status associated with the changes of content of pyridine
nucleotides in FVB and Mb hearts

NADH is a reducing agent produced primarily by glycolysis in the cytosol and by
the TCA cycle in mitochondria. NADH is a major substrate for ATP production. NAD+
is an oxidized form ofNADH. The ratio ofNADH to NAD also reflects the redox status
in cells. Hearts with lower glycolysis in Mb mice contained a lower content ofNADH
plus NAD+ compared to FVB sham (Figure 7A). T AC decreased the total content of
NAD(H) (the sum ofNAD+ and NADH) in both FVB and Mb hearts, and levels were
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similar in FVB-TAC and Mb-TAC (Figure 7A). NADH levels were similar in all groups
(Figure 7B). NAD+ content was reduced by TAC surgery and was significantly higher in
FVB-sham than in Mb sham (Figure 7C). TAC increased the ratio ofNADHINAD+ to
similar levels in FVB and Mb mice (Figure 7D). Due to the lower NAD+ content in Mbsham mice the NADHINAD+ ratio was higher in sham treated Mb than in FVB mice.

NADPH usually is regarded as a reducing agent that decreases oxidative stress.
NADP+ is the oxidized form ofNADPH. Mb hearts had lower total content ofNADP(H)
(the sum ofNADP+ and NADPH) compared to FVB hearts after sham or TAC treatment
(Figure 7E). TAC reduced NADP(H) in both FVB and Mb mice. TAC decreased
NADPH content in Mb and FVB mice but there were no significant differences between
Mb and FVB groups. NADP+ content was significantly reduced by TAC and NADP+
content was lower in Mb hearts than FVB hearts for both treatment groups. Due to the
reduction of both NADPH and NADP+, the ratio ofNADPH to NADP+ in FVB TAC did
not show a statistical change compared to FVB sham. In contrast, the ratio ofNADPH to
NADP+ in Mb TAC increased 3 fold compared to Mb sham and FVB TAC (Figure 7H).
This was primarily due to the very low NADP+ content in Mb TAC hearts (Figure 7G).

The ratio of total NADPH plus NADH to total NADP+ plus NAD+
(NAD(P)HINAD(Pt) is an indicator of reductive status and is shown in Figure 71.

Thirteen weeks after TAC , the ratio ofNAD(P)H to NAD(Pt increased 2-fold in both
FVB and Mb hearts. The ratio ofNADP(H)INAD(Pt in Mb TAC was significantly
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higher than in FVB TAC. Therefore, TAC increased reductive status and lower glycolysis
Mb hearts exhibited a more reduced status after TAC than FVB hearts.

Oxidative stress levels in FVB and Mb after TAC

The protein adduct of 4-hydroxynonenal (4HNE) is a marker of lipid peroxidation
and oxidative stress. Western blots of 4HNE adducts (Figure 8) were used to evaluate
oxidative stress levels in hearts. TAC increased the level of 4HNE adducts in both FVB
and Mb hearts. 4HNE was significantly higher in Mb-TAC than in FVB-TAC hearts.

DISCUSSION

Cardiac structural remodeling and dysfunction after TAC

PFK-l is one of rate limiting steps that control glycolysis. PFK-l activity can be
controlled by several factors such as citrate, ATP, ADP , H+, F-2,6-P 2

.

The metabolite

F-2,6-P2 is an especially important activator for PFK-l as shown in previous literature
(19, 108). Our laboratory demonstrated in vivo that a decrease ofF-2,6-P2 inhibited
glycolysis and an increase ofF-2,6-P2 enhanced glycolysis. TAC treatment increases F2,6-P2 content in the heart (66). After TAC, FVB and Mb both exhibited an increase ofF2,6-P2 content, however, Mb-TAC content was 37% lower than in FVB-TAC, implying
that glycolysis in Mb hearts is lower than in FVB hearts after TAC surgery.
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Cardiac specific reduction of glycolysis in Mb hearts resulted in more hypertrophy
and more severe fibrosis following cardiac insult by pressure over load. Hypertrophic
growth in the heart is mediated by growth factor pathways that increase protein synthesis,
induce enlargement of cardiomyocytes and promote reorganization of sarcormeres within
individual cardiomyocytes. The growth factor pathways for pressure overload (TAC) are
stimulated by mechanical stress on the heart. This stress can be transduced by intergrins
at focal adhesion sites on the cell surface to activate the src tyrosine kinase (50) and the
intergrin linked kinase (56), which is associated with the cytoskeletion and could
rearrange the actin skeleton, leading to hypertrophy. Mechanical stress on
cardiomyocytes also induces synthesis and secretion of potent growth factors such as
angiotensin 2 (Ang 2) and endothelin-l (ET-l) to stimulate heart growth (10,85, 115).
Decreased glycolysis in Mb mice might sensitize the heart to the growth factors Ang 2
and ET-1 and/or might predispose the heart to synthesize and secret more of these growth
factors. Elevated Ang2 and ET -1 can also stimulate fibroblasts to produce more fibrosis.
In addition, a decrease of glucose utilization would lead to elevation of fatty acid
oxidation due to the Randle cycle. Elevated fatty acid oxidation is associated with an
increase of oxidative stress. In our mice this possibility is supported by higher 4HNE
products in Mb TAC hearts compared to FVB-TAC hearts (Figure 8A and 8B). The
increase of oxidative stress may not only stimulate cardiac hypertrophy but also promote
fibrosis formation (57,97,98). Our data is supported by a cardiac insulin resistance study
in which hearts with Glut4 knockout showed cardiac hypertrophy, impaired contractility
and increased fibrosis (18, 35, 40) similar to our results. Furthermore the antioxidant
tempol prevented cardiac hypertrophy in the Glut4 knockout mice, suggesting that ROS
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also might playa role of the hypertrophy response in the Glut4-KO hearts (82) as well as
our Mb-TAC hearts.

Mb-T AC hearts also demonstrated more damaged cardiac function than FVB-TAC
hearts. This was manifested as a decrease of FS and a higher ratio of lung weight to tibia
length, in concert with increased LVEDD and L VESD. A number of membrane transport
systems are regulated preferentially by glycolytically generated ATP including the
sarcolemmal KATP channel, voltage-gated Ca2+ channels, the Na+-K+ pump, the Na+-H+
exchanger and the sarcoplasmic reticulum pump (25,54, 110, 112, 113). Inhibition of
glycolysis may have caused diastolic dysfunction (51) due to impairing ExcitationContraction (E-C) coupling, increasing intracellular Ca2 +concentration as well as
slowing ofCa2 + decay (48). The preferred energy substrate of the hypertrophied
myocardium is known to shift from fatty acids to glucose. The utilization of glucose in
Mb hearts was lower than in FVB hearts, consequently the glycolysis derived ATP in Mb
hearts would be expected to be lower. The importance of glycolysis derived ATP for
calcium pumps and channels could be a cause of abnormal calcium homeostasis in Mb
hearts. Abnormal calcium homeostasis combined with higher fibrosis ( Figure 2) might
result in diastolic dysfunction. Diastolic dysfunction was demonstrated by 37% increase
oflung weight to tibia length ratio (Figure 3) since impaired diastolic function leads to
lung congestion.

Human studies show that failing hearts have a lower PCrlATP ratio, which is a
marker of energy reserve and a predictor of mortality (69). The PCrlA TP ratio was
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significantly decreased in Mb-TAC hearts compared to FVB-TAC hearts (Figure 5).
Heart failure decreases PCrlA TP ratio, probably due to reducing the content of total
adenine nucleotides (90). It is possible this lessened glycolysis might enhance the
degradation of adenine nucleotides. The lower PCrlA TP ratio in Mb hearts indicates the
energy reserve declined more, thereby contributing to the reduction of systolic contractile
force. Furthermore, alpha MHC expression declined more in Mb TAC hearts ( p<0.05
vs. FVB TAC, Figure 4) in concert with lower FS and higher LVESD (Table 1).
Because alpha MHC has higher ATPase activity and higher filament sliding velocity than
beta MHC, down regulation of alpha MHC correlates with systolic dysfunction (83). In
addition, increase of alpha MHC expression is protective to the heart (39). Therefore, the
lower expression of alpha MHC in Mb-TAC hearts might contribute to the lower
contractile force in Mb hearts and probably hastened cardiac failure. All together, lower
glycolysis may not only have affected the function of membrane transporters but could
have also accelerated the degradation of adenine nucleotides and reduced the expression
of alpha MHC, thereby exacerbating impaired heart function under pressure overload.

Changes in pyridine nucleotide content associated with oxidative stress

After TAC, NADPH content declined to the same extent in both FVB and Mb
hearts (Figure 7). However, NADP+ content in Mb TAC decreased more than in FVBT AC. As a result, the ratio ofNADPH to NADP+ was 3 fold higher than in FVB TAC. If
the ratio of both reduced forms, NADH plus NADPH (NAD(P)H) to both oxidized
forms, NAD+ plus NADP+ (NAD(Pt) was calculated, the ratio NAD(P)HINAD(Pt was
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statistically higher in Mb TAC than that in FVB TAC hearts, indicating that the Mb-TAC
hearts were in a more reduced state. Beyond a certain level, an increased reductive state
has been linked to greater cellular oxidative stress (4). This may be because higher
NADH and NADPH in mitochondria could cause saturated electron flow in the electron
transfer chain (ETC). Some of these electrons can leak out and combine with oxygen,
producing superoxide (13). If the mitochondrial ETC was damaged, leakage of electrons
could increase and more superoxide would be produced. TAC results in mitochondrial
dysfunction in parallel with systolic dysfunction (17). Therefore, the higher ratio of
NAD(P)H to NAD(P)+ in Mb-TAC hearts could cause stronger oxidative stress from
mitochondria. Greater oxidative stress was manifested in Mb-TAC hearts as a higher
level of 4HNE adducts (Figure 8). More oxidative stress in the heart is likely to promote
damage to multiple components of the cardiomyocyte. Thus the increased reductive state
in Mb-TAC hearts may have accelerated the progression of heart failure via increased
oxidative stress.

In summary, Mb hearts with reduced glycolysis exhibited greater heart failure
after TAC surgery as measured by several parameters including more severe cardiac
structural and functional changes, more abnormal energetic status, higher reductive status
and higher oxidative stress. These results suggest that decreasing cardiac glycolysis, as
occurs in diabetes, can have an important role in the development of diabetes induced
heart failure.
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Table 1. Cardiac function measured by echocardiography in FVB and Mb mice 13
weeks after T AC or sham surgery
parameter

FVB sham

FVBTAC

Mb sham

MbTAC

BW(g)

30.4::1:0.8

30.8::1:0.8

29.3::t0.7

30.6::t0.9

LVEDD (mm)

3.81::1:0.08

4.15::1:0.05"

3.97::1:0.08

4.40::l:0.0S;l.b

LVESD (mrl)

2.36::1:0.10

2.48::1:0.07

3. 17::1:0.0ga.b

IVS (D) (mm)

0.91::1:0.02

2.76::1:0.081.02::1:0.03a

0.86±0.03

1. 03::1:0. 02a

IVS (5) (mm)

1.18::1:0.03

1. 29±0.03a

1.13±0.02

1.25±0.02a

PlNTh (C)(mm)

0.80±0.04

0.74±0.02

0.88±0.OJa

PlNTh (S)(mm)

1.16::1:0.04

0.89±0.03a
1. 25::1:0.02a

1.11::1:0.04

1.2S::I:0.OSa

IVS%Th

30.9::1:2.8

29.3::1:3.5

33.6::1:3.6

24.1::1:2.26

PIN%Th

40.7::1:5.2

40.3::1:3.8

44.7::1:1.9

42.0::1:4.0

IVS!PW

1.16::1:0.05

1.13±0.03

1.15±0.04

%FS

38.6::1:1. 7

33.8::1:1.1"

37.4::1:1.3

1.15±0.05
27.1::1:1.1 a,b

HR

487:i::10

516:i::11

533:i::7

525:i::16

------.----.-----
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Legend: Data are mean±SE. a, p<O.05, FVB-sham vs. FVB-TAC or Mb-sham vs. MbTAC; b, p<O.05, Mb-TAC vs. FVB-TAC by two way ANOVA analysis, n=8 for sham
groups, n=12 for TAC groups. LVEDD, left ventricular end diastolic diameter; LVESD,
left ventricular end systolic diameter; IVS( d), interventricular septum thickness at
diastole; IVS(s), interventricular septum thickness at systole; PWTh(d), post wall
thickness at diastole; PWTh(s), post wall thickness at systole; IVS%Th, interventricular
septum % thickening; PW% Th, posterior wall % thickening; IVS/PW, interventricular
septum to posterior wall thickness ratio; %FS, percent fractional shortening; HR, heart
rates.
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Figure 1. The Mb transgene exacerbates TAC induced hypertrophy. Mice were
sacrificed 13 weeks after surgery. Panels A and B show representative whole hearts and
transverse cardiac cross-sections, respectively. The graph in panel C shows heart weight
to tibia length. Both FVB and Mb TAC hearts were larger than sham hearts. Mb-TAC
hearts were larger than FVB-TAC hearts. *, p<O.OI, sham vs. TAC; #, p<O.05, Mb-TAC
vs. FVB-TAC by two way ANOVA, n=7 for FVB-sham, n= I 0 for FVB-TAC, n=5 for
Mb-sham and n=7 for Mb-TAC.
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Figure 2. Fibrosis is increased in Mb hearts 13 weeks after TAC. (A) Representative
sirius red staining for fibrosis in FVB and Mb hearts. (B) Semi-quantitative scores for
fibrosis staining performed as described in Methods by a blind observer. Staining of
fibrosis in Mb-TAC hearts was significantly higher than that in FVB-T AC hearts. The
expression of collagen Ia mRNA (panel C) measured by quantitative RT-PCR was
significantly higher in Mb-T AC hearts than in FVB-T AC hearts. Expression of collagen

3a mRNA (panel D) was elevated in T AC hearts but not significantly different in MbTAC versus FVB-TAC hearts. #, P<O.05, Mb-TAC vs. FVB-TAC and *, P<O.05, Sham
vs. TAC by 2-way ANOYA, n=5 for each group.
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Figure 3. The ratio of lung weight to tibia length 13 weeks after T AC in FVB and
Mb mice. TAC significantly increased the ratio of lung weight to tibia length in Mb but
not in FVB mice. *, p<O.OI, Mb-sham vs. Mb-TAC; #, p<O.05, Mb-TAC vs. FVB-TAC
by two way ANOV A analysis, n=7 for FVB-sham, n= 10 for FVB-TAC, n=5 for Mbsham and n=7 for Mb-TAC.
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Figure 4. Hypertrophic biomarkers BNP (A), ANP (B), P-MHC (C) and a-MHC (D)
mRNAs analyzed by quantitative RT-PCR in FVB and Mb hearts 13 weeks after
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Figure 5. The content of ATP and phosphocreatine (PCr) and the ratio of PCr to
ATP in FVB and Mb hearts. (A) and (B) TAC decreased the content ofPCr and ATP,
however, the differences between FVB and Mb were not significant. (C) TAC decreased
the ratio of PCr to ATP in both FVB and Mb mice, moreover, the ratio was lower in MbTAC than in FVB-TAC. *, P<O.OI, sham vs. TAC; #, P<O.05, FVB TAC vs. Mb TAC by
two way ANOV A, n=8 for Mb-TAC, n=5 for other groups.
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Figure 6. The content F-2,6-P2, lactate and pyruvate in FVB and Mb hearts. (A)
Cardiac F-2,6-P2 content was elevated in both groups ofTAC mice but always higher in
FVB hearts than in Mb hearts. (B) In sham hearts lactate content was lower in Mb mice
but in TAC hearts lactate content was similar in Mb and FVB hearts. (C) Mb sham had
two fold higher pyruvate content than FVB sham. After TAC, pyruvate content decreased
significantly in Mb but not in FVB hearts, as a consequence no significant difference was
found in the pyruvate content between FVB-TAC and Mb-TAC. (D) The ratio oflactate
to pyruvate in Mb-sham was about one third of that in FVB-sham. After TAC, the ratio of
lactate to pyruvate declined in FVB, in contrast, the ratio increased in Mb relative to
sham controls respectively. The ratio oflactate to pyruvate in FVB-TAC and Mb TAC
was not different. Statistical analysis was done by two way ANOVA, *, p<O.05, sham vs.
TAC; #, p<O.05, Mb-sham vs. FVB-sham or Mb-TAC vs. FVB-TAC, n=5 for FVBsham, Mb-sham and FVB-TAC, n=8 for Mb-TAC.
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Figure 7. The content of pyridine nucleotides in FVB and Mb hearts. (A) The total of
NADH and NAD+ content in Mb-sham was reduced to half of that in FVB-sham. After
TAC, the total content ofNADH plus NAD was decreased significantly in both FVB and
Mb hearts, and no significant difference was found between FVB-TAC and Mb-TAC. (B)
NADH content was similar in FVB and Mb hearts in all groups. (C) The content ofNAD
in Mb-sham was significantly lower than in FVB-sham. After TAC, NAD content
decreased significantly in both FVB and Mb hearts, whereas no significant difference
was found between FVB-TAC and Mb-TAe. (D) The ratio ofNADH to NAD was
significantly higher in Mb-sham than in FVB sham. After TAC, the ratio in FVB and Mb
went up significantly, whereas no significant difference was found when comparing
FVB-TAC with Mb-TAC. (E) The total ofNADPH and NADP+ content decreased by
30% in Mb-sham compared to FVB-sham. TAC reduced the total ofNADPH and
NADP+ content in both FVB and Mb hearts, furthermore, the content of total NADPH
plus NADP in Mb-TAC was significantly lower than in FVB-TAe. (F) A significant
decrease ofNADPH content was observed in FVB and Mb hearts after TAC. The
NADPH content was constant in FVB-sham and Mb-sham while no significant difference
was found between FVB-TAC and Mb-TAC. (G) NADP+ content was lower in Mb-sham
compared to FVB-sham. TAC decreased NADP+ content in both FVB and Mb hearts and
NADP+ content in Mb-TAC was significantly lower than in FVB-TAe. (H) TAC
increased the ratio ofNADPH to NADP+ in Mb but not in FVB hearts. Furthermore, the
ratio in Mb-TAC was significantly higher than in FVB-T AC. (1) The ratio of reduced
pyridine nucleotides, NADPH plus NADH to oxidized nucleotides, NADP+ plus NAD+
was significantly increased in both FVB and Mb hearts after TAC, and the ratio in Mb-
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TAC was significantly greater than in FVB-TAC. *, p<O.05, sham vs. TAC; #, p<O.05,
Mb-sham vs. FVB-sham or Mb-TAC vs. FVB-TAC by two way ANOV A analysis, n=8
for Mb-TAC and n=5 for other groups.
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Figure 8. Oxidative stress shown by 4HNE adducts in FVB and Mb hearts. (A)
Representative western blot of 4HNE adducts and GAPDH for loading control. (B)
Statistical results of 4HNE adducts normalized by GAPDH. TAC increased the 4HNE
adducts in both FVB and Mb hearts. Mb-TAC exhibited more 4HNE adducts than FVBTAC. *, p<O.05, sham vs. TAC; #, p<O.05, Mb-TAC vs. FVB-TAC by two way ANOV A
analysis, n=6 for each group.
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CHAPTER II

INCREASED GLYCOLYSIS INCREASES SUSCEPTIBILITY TO CARDIAC
HYPERTROPHY AND HEART FAILURE
INTRODUCTION
Heart failure remains the leading cause of mortality in USA. Chronic
hemodynamic overload from hypertension, valvular disease or postmyocardial infarction
can cause cardiac hypertrophy as a compensatory response. With long term hypertrophy,
however, cardiac hypertrophy may evolve into failure, and the underlying mechanism for
this transition is poorly understood. A common feature of cardiac hypertrophy and failure
is increased glycolysis. This finding is supported by human and animal studies (3, 9, 41,
73,96, 117) . The increase of glycolysis is thought to be adaptive and beneficial (53, 60,
106). The mechanisms for increased glycolysis in hypertrophied heart includes increased
glucose uptake by glucose transporters and elevation ofF-2,6-P2 Ievel to enhance PFK-l
activity (66). Tian's group (53) used cardiac specific over expression of the Glutl
transporter to increase glycolysis in the heart. The Glut 1 trans gene exhibited a protective
effect on the heart after aortic banding (53). We used another molecule, fructose-2,6-P2 (
F-2,6-P2) rather than glucose transporter, to elevate glycolysis in the heart (l08). In
contrast to the results from Glut! trans gene, our transgenic hearts with high glycolysis
induced by elevated levels ofF-2,6-P 2 exhibited detrimental effects after banding.
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MATERIALS AND METHODS

Animals
The control and Mk mice used were male and kept on the FVB background.
Studies were begun at age 90-100 days and body weight of26-30g.

Transaortic constriction (TAC) surgery and Echocardiographic Assessment of
Cardiac Function
TAC surgery was performed by a modification a previously published (6) as
described in chapter I of this dissertation. Transthoracic echocardiography of the left
ventricle was performed using a I5-MHz linear array transducer (15L8) interfaced with a
Sequoia C5I2 system (Acuson) as previously described (109) and as detailed in chapter I
of this dissertation.

Western blot, Quantitative Real Time Polymerase Chain Reaction (RT-PCR),
Histological experiments, Metabolites measurement and Statistical analysis
The procedures used for these techniques are described in detail in the Methods section of
Chapter I

RESULTS

Cardiac structural and functional changes 13 weeks after TAC
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TAC was applied for 13 weeks. Both Mk and FVB hearts increased in size
(Figure 9A), and hearts from Mk mice appeared larger than those ofFVB mice (Figure
9A) after TAC. The change in appearance was also seen in transverse cross-sections of
hearts (Figure 9B). The ratio of heart weight to tibia length was used to quantify the
morphology change. Heart weight to tibia length ratio increased by 49% in FVB hearts
and by 85% in Mk hearts after TAC, and there was a significant difference between FVBTAC and Mk-TAC (Figure 9C). This result suggests that Mk hearts with increased
glycolysis developed more hypertrophy in response to external pressure overload stimuli
than normal FVB hearts.

Echocardiography was used to assess cardiac structural and functional changes.
Left ventricular end diastolic diameter (L VEDD) and left ventricular end systolic
diameter (LVESD) in both FVB and Mk hearts increased significantly after TAC,
however, no significant difference was found between FVB TAC and Mk TAC (Table 2).
Fractional shortening (FS) in both FVB and Mk decreased significantly after TAC,
concomitantly with the changes ofLVEDD and LVESD. Furthermore, FS in Mk-TAC
declined by 12% compared to FVB-TAC (Table 2) and FS was significantly lower in
Mk-TAC hearts. These results indicate that cardiac structure and function in Mk hearts
with increased glycolysis were damaged more than in FVB hearts when subject to
overload by external pressure.

Fibrosis was examined to evaluate cardiac remodeling due to TAC in Mk and
FVB hearts (Figure 10). Figure lOA shows representative pictures of fibrosis staining by
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Sirius Red and figure lOB shows semi quantitative analysis of the staining. Fibrosis
scores were increased in both FVB and Mk hearts after TAC, whereas the scores in MkT AC were statistically higher than in FVB-TAC. The expression of collagen 1 and
collagen 3 mRNA level confirmed the results of fibrosis staining (Figure 10C and 10D).
The mRNA level of collagen 1 and collagen 3 were elevated significantly (p<O.OI) in Mk
and FVB after TAC and the expression of collagen 1 mRNA and 3 mRNA level was
higher (p<O.05) in Mk-TAC compared to FVB-TAC hearts (Figure 10C and lOD). The
greater fibrosis in Mk hearts indicates that increased glycolysis might promote more
severe cardiac remodeling.

Lung weight to tibia length ratio is a good indicator of heart failure. This
parameter was also measured to evaluate heart function. Thirteen weeks after TAC, FVB
mice did not exhibit any significant change in the lung weight to tibia length ratio. In
contrast, Mk mice showed a significant elevation of the lung weight to tibia length ratio
(Figure 11). Furthermore, the ratio in Mk-TAC increased by 61 % (p<O.05) compared to
FVB-TAC. This implies that hearts with increased glycolysis reached more severe heart
failure than hearts with normal glycoysis in response to external pressure overload.
Therefore, the hearts with increased glycolysis in Mk mice seems to be more vulnerable
to the pressure overload stimulus, exhibiting a greater hypertrophy response and a more
severe decrease of cardiac function.

Changes of energetic status in FVB and Mk hearts after TAC and sham surgery
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Due to the decrease of systolic function after TAC, the supply of high energy
compounds, ATP, and phosphocreatine (PCr) and the ratio ofPCr to ATP were
measured. The ratio of PCr to A TP is the most widely used indicator of cardiac muscle
reserve. After TAC, ATP content was significantly decreased in FVB, while TAC
reduced the ATP content in Mk mice but without reaching significance (Figure 12A). In
addition, TAC decreased the level of PCr and the ratio of PCr to ATP (P<O.05) in both
FVB and Mk mice (Figure 12B and 12C). Regarding the levels of ATP and PCr, there
were no significant difference between FVB-sham and Mk-sham and between FVB-TAC
and Mk-TAC (Figure 12A and 12B), whereas, the ratio ofPCr to ATP was a significant
decreased by 28% in Mk-TAC compared to FVB- TAC hearts (Figure 12C). Thus, TAC
decreased energy reserve in hearts, and hearts with higher glycolysis in Mk mice
potentiated the reduction of energy reserve. This reduction of energy reserve might
contribute to systolic dysfunction in Mk mice.

Hypertrophic biomarkers of expression of BNP, ANP, P-MHC and a-MHC mRNA

Mk mice exhibited more hypertrophy, manifested as an elevated ratio of heart
weight to tibia length after TAC. The hypertrophic biomarkers BNP, ANP,

~-MHC

and

a-MHC mRNA were investigated by RT-PCR in both Mk and FVB mice. The expression
ofBNP, ANP and

~-MHC

mRNA level increased significantly in both Mk and FVB mice

after TAC, whereas no statistical differences were found between FVB-TAC and MkTAC hearts, and between FVB-sham and Mk-sham hearts (Figure 13A, 13B and 13C).
The expression level of a-MHC mRNA decreased significantly in both FVB and Mk
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mice after TAC, however, without a significant changes in Mk-TAC compared to FVBTAC (Figure 13D).

The levels of fructose-2,6-P2, glucose-6-phosphate, lactate and pyruvate metabolites
after TAC and sham surgery

The level of fructose-2,6-P 2( F-2,6-P2 ) was manipulated to control glycolysis in
Mk mice, in which the content ofF-2,6-P 2 was 7 fold higher than that in FVB wild type (
1.06±O.08 vs.7.58±O.72 nmoles/g wt in FVB-sham and Mk sham, respectively, p<O.OI,
Figure 14A). Thirteen weeks after TAC the content ofF-2,6-P2 was increased in both
FVB and Mk hearts and the F-2,6-P 2 Ievel in Mk-TAC (9.69±O.37 nmoles/g wt) was still
higher than that in FVB-TAC hearts (1.34±O.06 nmoles/g wt, p<O.05, Figure 14A),
suggesting that glycolysis continued to be higher in Mk hearts. Glucose-6-phosphate (G6-P) levels were lower in Mk-sham hearts than in FVB-sham hearts (p<O.05). TAC
further decreased the content of G-6-P in both FVB and Mk hearts, with a significantly
lower G-6-P level in Mk-TAC than in FVB-TAC hearts (Figure 14B). Since G-6-P is
upstream ofPFKI the lower levels ofG-6-P in Mk hearts is consistent with more active
PFKI due to higher levels ofF-2,6-P2 in Mk hearts both before and after TAC. Lactate is
a product of glycolysis, and therefore has been used as an indirect indicator of glycolysis.
As expected, lactate in Mk-sham hearts (4.56±O.52 umoles/g wt) increased by 68%
compared to FVB-sham hearts (2.71±O.24 umoles/g wt, Figure 14C), consistent with the
elevation ofF-2,6-P2 in Mk mice (Figure 14A). TAC decreased lactate in FVB and Mk
mice, perhaps because of higher glucose oxidation rates following TAC. After TAC,
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lactate in Mk hearts was two-fold higher than in FVB hearts (Figure 14C). Pyruvate
content in Mk hearts was also higher than in FVB hearts, either with or without TAC
surgery (Figure 14D). The higher content oflactate and pyruvate, which are both
downstream products of the key glycolytic enzyme PFKl, are consistent with elevated
glycolytic rate in Mk hearts before and after TAC surgery.

The changes of redox status associated with the changes of content of pyridine
nucleotides in FVB and Mk hearts

NADH is produced primarily by glycolysis in the cytosol and the TCA cycle in
mitochondria. NADH is a major substrate for ATP production. NAD+ is the oxidized
form ofNADH. The ratio ofNADH to NAD+ reflects the redox status in cells. Mk hearts
exhibited a lower total content ofNADH plus NAD+ compared to FVB-sham hearts
(Figure 15A). TAC decreased the total content ofNAD(H) (NADH plus NAD+)in FVB
hearts but not in Mk hearts (Figure 15A). NADH content was lower in Mk-sham than
FVB-sham hearts (Figure 15B). TAC did not have any effects on NADH level in FVB
mice (Figure 15B), but unexpectedly TAC increased NADH levels in Mk hearts (Figure
15B). Similar to NADH, NAD+ levels were also lower in Mk-sham than in FVB-sham
(Figure 15C). TAC decreased the NAD+ level in FVB hearts and had no significant effect
on NAD+ content in Mk hearts (Figure 15C). Consequently, NAD+ levels in Mk-TAC
and FVB-TAC hearts were similar (Figure 15C). The ratio ofNADH to NAD+ was
significantly increased in both FVB and Mk hearts by TAC, but there were no significant
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differences in this ratio between Mk and FVB hearts for either sham or TAC groups (
Figure 15D). Therefore, in FVB hearts the reason for the increased ratio ofNADH to
NAD+ after TAC was the decline in NAD+ content. Conversely, in Mk hearts the ratio of
NADH to NAD+ increased after TAC because NADH content went up.

NADPH is produced primarily by the cytosolic pentose phosphate pathway and is
important for antioxidant protection. NADP+ is the oxidized form ofNADPH. Mk-sham
hearts exhibited a lower total content ofNADP(H) compared to FVB-sham hearts (
Figure 15E). After TAC, the total content ofNADP(H) decreased significantly in FVB
but not in Mk hearts ( Figure 15E). Mk-sham hearts exhibited a lower level ofNADPH
compared to FVB-sham hearts (Figure 15F). TAC decreased the level ofNADPH in
FVB mice (Figure 15F). Unexpectedly, TAC increased NADPH content in Mk-TAC
hearts to a significantly higher level than in Mk-sham or FVB-TAC hearts (Figure 15F).
Mk-sham and Mk-TAC hearts exhibited a significantly lower level ofNADP+ than the
corresponding FVB groups (Figure 15G). TAC lowered NADP+ levels in Mk and FVB
hearts. Since TAC both increased NADPH and reduced NADP+ in Mk hearts the ratio of
NADPH to NADP+ was very high in Mk-TAC hearts (Figure 15H) and this was
significantly higher than any other group.

The combined reductive pyridine nucleotide status, an indicator of overall
cellular reductive status can be calculated as the ratio of total NADPH plus NADH to
total NADP+ plus NAD+ (NAD(P)HINAD(Pt) as shown in Figure 151. Thirteen weeks
after TAC surgery, the ratio ofNAD(P)H to NAD(Pt was elevated significantly in both
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FVB and Mk hearts. The ratio ofNADP(H)/NAD(Pt in Mk-TAC was statistically higher
than in FVB-TAC.

Oxidative stress marker in FVB and Mk hearts after T AC surgery

The protein adduct of 4-hydroxynonenal (4HNE) is a marker of lipid peroxidation
and oxidative stress. 4HNE western blots (Figure 16) were used to evaluate oxidative
stress levels in hearts. TAC increased the level of 4HNE adducts in both FVB and Mk
mice, without a significant difference between Mk-TAC and FVB-TAC groups.

DISCUSSION

PFK-l is one of rate limiting steps that control glycolysis. PFK-l activity can be
controlled by several factors such as citrate, ATP, ADP , H+, F-2,6-P 2. In our Mk
transgenic mice, F-2,6-P2 was increased several fold before and after TAC, which
activates PFK-l, increases glycolysis measured in perfused hearts by 50% (l08) and
decreases Glucose-6-P (G-6-P) levels. The decrease in G-6-P content is consistent with
the concept that increased PFK-l activity will reduce the level ofPFKl substrates. The
reduction ofNADPH level in Mk-sham hearts (Figure 15F) may have been due to the
lower level ofG-6-P in Mk hearts, since G-6-P is the first substrate of the pentose
phosphate pathway, which produces NADPH. Unexpectedly NADPH levels were much
higher in Mk-TAC hearts than in FVB-TAC or Mk-sham hearts (Figure 15F). Since
NADPH has antioxidant value, this suggests that Mk-TAC could be protected from
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oxidative stress. However, Mk TAC hearts demonstrated the same level of 4HNE adducts
as FVB TAC hearts (Figure 16), suggesting that oxidative stress might not be the reason
for greater deterioration of cardiac function in Mk-TAC compared to FVB-TAC hearts.

The paradoxical finding of lower G-6-P content, concurrently with higher
NADPH levels in Mk-TAC hearts suggests that the higherNADPH was probably
produced from pyridine nucleotide transhydrogenases in mitochondria rather than from
the pentose pathway in the cytosol. NADH can reduce NADP+ to NADPH by
mitochondrial transhydrogenases (31, 94), which can account for 45% of the total
NADPH supply. The remainder is provided by NADP+ dependent isocitrate
dehydrogenase and the mitochondrial NADP+ dependent malic enzyme (86, 89, 105).
NAD+ cannot diffuse between cytosol and mitochondria (111). Thus, a question should
be raised about the balance ofNADPH in cytosol versus mitochondria. Therefore, the
change of cyotosolic and mitochondrial NADPH level is worth investigating in Mk-TAC
hearts, to possibly explain the lower content of G-6-P concurrent with high levels of
NADPH and the lack of protection from oxidative stress.

Comparison of cardiac energy reserves in Mk mice to another transgenic model of
increased glycolysis

A transgenic mouse with cardiac specific overexpression of the Glut1 transporter
produced 40 fold higher glucose uptake, 5 fold higher cardiac glycogen and markedly
increased lactate (53). This indicated that Glut! overexpression increased glycolysis and
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caused increased cardiac content of glycolytic metabolites. Although glycolysis was
increased in both Mk and Glut! transgenic hearts, the different levels of PFK activity and
glucose uptake might have different effects on the heart. After aortic banding, the Glut!
trans gene exhibited a protective effect with preserved energy reserve e.g. higher

PCr/ATP ratio (53). In contrast, the Mk transgene produced a detrimental effect after
T AC with lower energy reserve e.g. lower PCrlA TP ratio. This suggests that increased
glycolysis initiated by the glucose transporter or initiated by elevation of PFK-1 activity
have opposite effects on energy reserve in the stressed heart. Human studies showed that
failing hearts have a lower PCr/ATP ratio, which predicted mortality(69). Animal studies
demonstrated that TAC decreased the PCr/ATP ratio probably due to reduction of total
adenine nucleotide content (90). Therefore, increased glycolysis by increased rate of
glucose uptake via glucose transporter higher than PFK-l activity might preserve the
TAN (total adenine nucleotide) content, whereas increase of glycolysis by elevation of
PFK activity higher than the rate of glucose uptake via glucose transporter might
potentiate the reduction of TAN after banding.

Mk exacerbation of TAC injury to the heart

Cardiac specific increased glycolysis by elevation ofF-2,6-P 2 level in Mk hearts
produced more hypertrophy, more severe fibrosis, lower energy reserves and more
impaired cardiac function following pressure over load. The mechanistic basis for the
negative effects of Mk are not yet certain and will require a further understanding of the
basis of cardiac hypertrophy and heart failure. The purpose of cardiac hypertrophy is to
relieve stress on the ventricular wall. The mechanical stress produced by TAC can cause

50

intergrins to activate src tyrosine kinase (50) and the intergrin linked kinase (56), leading
to rearrangement of actin skeleton, while mechanical stress could also induce synthesis
and secretion of potent growth factors such as angiotensin 2 ( Ang 2) and endothelin-I (
ET -1) to stimuli heart growth (10, 85, 115). Therefore, it is possible that increased
glycolysis by elevation ofthe F-2,6-P2 level in Mk hearts might amplify the src tyrosine
kinase or intergrin linked kinase signals or change the behavior of Mk cardiomyocytes to
secrete more Ang2 or ET-1 under stress conditions, which could also impact fibroblasts
to produce more fibrosis.

Mk trans gene summary

In summary, Mk hearts after TAC exhibited more severe structural and
functional changes than FVB hearts. Since a publication reported that elevation of
glycolysis by the Glut 1 transporter protected hearts from pressure overload, it appears
that the mechanism of glycolysis elevation is critical. Our current results suggest that
therapeutic interventions in heart failure aimed at altering metabolism to protect the heart
would be better by focusing on increasing glucose uptake, rather than increasing PFK1
activity. Our results also suggest that the increase F-2,6-P 2 content that occurs in failing
hearts is more likely to be detrimental rather than a beneficial, adaptive response.
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Table 2. Cardiac function measured by echocardiography in FVB and Mk mice 13
weeks later after TAC or sham surgery
parameter

FVB sham

FVBTAC

Mk sham

MkTAC

BW (g)

30.4:tO.8

30.8:tO.8

30.8:t1.3

29.4:tO.9
4.18:1:0.06

(r11lT1)

3.81:1:0.08

4.15:1:0.0Sa

4. 13:1:0.06 c

LVESD (mm)

2.36:t0.10

2.76±0.OSa

2.46±0.07

IVS I,d) (mm)

0.91:t0.02

1.02±0.03a

0.94±0.02

2.95:1:0.07a
1.02:t0.03a

rvs

1. 18:tO.03

1. 29:tO.03

1.3:tO.04

1. 28:tO.03

PWTh (d) (mm)

0.80:1:0.04

0.79:1:0.02

PWTh (5) (mm)

1.16:1:0.04

0.89±0.03a
1.25±0.02a

1.20:1:0.03

0.92:1:0.03a
1. 28:t0.03a

TVS%Th

30.9:1:2.8

29. 3±3. 5

38.2±4.9

26.9:1:4.7

PW%Th

40.7:15.2

40.3:1:3.8

55.6:1:2.8

40.7:13.1

IVS(PVV

1.16:1:0.05

1.13±0.03

1. 22±0.04

1.12:1:0.04

%FS

3S.6:t1.7

33.8:t1.1"

40.4:t1.1

29.6:t1. 33 ,b

516:tll

475:t1S

L VEDD

(5) (mm)

487:tlO
HR
-----------_._._----_._
...._- .... _._----"---_._-
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525:t12

----------"

--, ... _...._--_._------_._---.-_.----------------_ ....

Legend: Data are mean±SE. a, p<O.05, FVB-sham vs. FVB-TAC or Mk-sham vs. MkTAC; b, p<O.05, Mk-TAC vs. FVB-TAC; c, p<O.05, Mk-sham vs. FVB-sham by two
way ANOV A analysis, n=8 for sham groups, n= 12 for TAC groups. LVEDD, left
ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; lVS(d),
interventricular septum thickness at diastole; lYSes), interventricular septum thickness at
systole; PWTh(d), post wall thickness at diastole; PWTh(s), post wall thickness at
systole; lVS% Th, interventricular septum % thickening; PW% Th, posterior wall %
thickening; lVS/PW, interventricular septum to posterior wall thickness ratio; %FS,
percent fractional shortening; EF, ejection fraction; HR, heart rates.
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Figure 9. The

chang(~s

of whole heart morphology and heart weight to tibia length

ratio in FVB and Mk hearts 13 weeks after TAC. (A) Representative morphology of
whole hearts 13 weeks after TAC. (B) Representative transverse cross-sections of hearts
after TAC, confirming the hypertrophy of whole hearts in (A). (C) The ratio of heart
weight to tibia length after TAC. Both FVB and Mk had significantly higher heart weight
to tibia length ratio after TAC, moreover, the ratio in Mk-TAC was significantly higher
than that in FVB-TAC. *, p<O.OI, sham vs. TAC; #, p<O.05, Mk-TAC vs. FVB-TAC by
two way ANOVA analysis, n=7 for FVB-sham, n=lO for FVB-TAC, n=6 for Mk-sham
and n=9 for Mk-TAC.
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Figure 10. Fibrosis in FVB and Mk hearts 13 weeks after TAC. (A) Representative
staining for fibrosis in FVB and Mk hearts after sham and TAC surgery. (B) Semiquanititative analysis of fibrosis measured by staining with Sirius Red and scored by
estimating fibrosis: staining graded as 1 for low, 2 for mild, 3 for moderate and 4 for
severe. The staining of fibrosis in Mk and FVB was increased significantly after T AC,
moreover, the fibrosis staining scores in Mk-TAC was significantly higher than the
scores in FVB-TAC. (C) and (D) The expression of collagen 1 and collagen 3 mRNA
was analyzed by quantitative RT-PCR. The expression of collagen 1 and 3 mRNA was
increased significantly in both FVB and Mk mice after TAC, furthermore, the expression
of collagen 1 mRNA and collagen 3 mRNA was significantly higher in Mk-TAC
comparing with FVB-TAC, confirming the fibrosis staining in (A) and (B). *, p<O.05,
sham vs. TAC; #, P<O.05, Mk-TAC vs. FVB-TAC by two way ANOVA analysis, n=5
for each group.

57

eE

25

-oSE

20

=

15

i:n
tn
II

IOSham .lACI

.. ,.

...I
~

:c
i=

...

10

.z:.

tn

I

5

tn

=
::

...I

0

FVB

Mk

58

Figure 11. The ratio oflung weight to tibia length 13 weeks after TAC in FVB and
Mk mice. TAC significantly increased the ratio of lung weight to tibia length in Mk not
in FVB mice. Further analysis revealed that Mk-TAC had significantly higher ratio of
lung weight to tibia length than FVB-TAC. *, p<O.Ol, Mk-sham vs. Mk-TAC; #, p<O.05,
Mk-TAC vs. FVB-TAC by two way ANOVA analysis, n=7 for FVB-sham, n=lO for
FVB-TAC, n=8 for Mk-sham and n=12 for Mk-TAC.
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Figure 12. The content of ATP and phosphocreatine (PCr) and the ratio of PCr to
A TP in FVB and Mk hearts after TAC 13 weeks. (A) TAC significantly decreased the
level of ATP in FVB and Mk hearts to a similar level. No significant difference was
found between FVB-sham and Mk-sham and in between FVB-TAC and Mk-TAC. (B)
T AC decreased the content of PCr in both FVB and Mk, however, no significant
difference was found between FVB-sham and Mk-sham and between FVB-TAC and MkTAe. (C) TAC decreased the ratio ofPCr to ATP in both FVB and Mk mice,
furthermore, a significant decrease of the ratio was found in Mk-TAC compared to FVBTAe. *, p<O.OI, sham vs. TAC; #, p<O.05, FVB-TAC vs. Mk-TAC by two way ANOVA
analysis, n=5 for each group.
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Mk

Figure 13. Hypertrophic biomarkers BNP, ANP, P-MHC and a-MHC mRNAs were
analyzed by RT-PCR in FVB and Mk hearts 13 weeks after TAC. (A), (B) and (C)
The expression of ANP, BNP and

~-MHC

was increased significantly in both Mk and

FVB mice after TAC, however, no significant differences were found between FVB-TAC
and Mk-TAC. (D) The expression of a-MHC mRNA decreased significantly in both FVB
and Mk hearts after TAC, without significant difference between Mk-TAC and FVBTAC. *, p<O.05, sham vs. TAC by two way ANOVA analysis, n=5 for each group.
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Figure 14. The content of fructose-2,6-bisphosphate (F-2,6-P2), glucose-6-phosphate,
lactate and pyruvate in FVB and Mk hearts 13 weeks after TAC. (A) Mk-sham had 6
fold higher F-2,6-P2 content than FVB-sham. TAC increased the content ofF-2,6-P 2 in
both FVB and Mk hearts, however, F-2,6-P2 content in Mk-TAC was still much higher
than in FVB-TAC. (B) The glucose-6-phosphate content declined in Mk-sham. TAC
decreased the level of glucose-6-phosphate in both FVB and Mk mice, with a
significantly lower level of glucose-6-phosphate in Mk-T AC compared to FVB-T AC.
(C) Lactate content in Mk-sham elevated significantly compared to FVB-sham. After
TAC, both FVB and Mk exhibited a significant reduction of lactate, whereas the lactate
content in Mk-TAC was still higher than in FVB-TAC. (D) TAC did not change the
content of pyrvuate in both FVB and Mk after sham and T AC surgery, however, the
pyruvate content in Mk was always higher than FVB, with or without T AC. The
statistical analysis was done by two way ANOVA, *, p<O.05, sham vs. TAC; #, p<O.05,
Mk-sham vs. FVB-sham or Mk-TAC vs. FVB-TAC, n=5 for each group.
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Figure 15. The content of pyridine nucleotides in FVB and Mk hearts 13 weeks after
TAC. (A) The total ofNADH and NAD+ content in Mk sham was reduced to half of that
in FVB-sham. After TAC, the total content ofNADH and NAD+ content was decreased
significantly in FVB but not in Mk hearts, and no significant difference was found
between FVB-TAC and Mk-TAC. (B) NADH content was similar in FVB with and
without TAC. Mk-sham contained lower NADH content than FVB-sham. However, after
TAC, NADH content in Mk hearts was back to levels found in FVB-sham. (C) The
content ofNAD+ in Mk-sham was significantly lower than in FVB-sham. After TAC,
NAD+ content decreased significantly in FVB but not in Mk hearts relative to sham. No
significant difference was found between FVB-TAC and Mk-TAC. (D) The ratio of
NADH to NAD+ was similar between Mk-sham and FVB-sham. After TAC, the ratio in
FVB and Mk went up significantly, whereas no significance was found when comparing
FVB-TAC with Mk-TAC. (E) The total ofNADPH and NADP+ content decreased by
50% in-Mk sham compared to FVB-sham. TAC reduced the total ofNADPH and
NADP+ content in FVB. In contrast, TAC increased the total ofNADPH and NADP+
content in Mk, as a consequence, the content of total NADPH and NADP+ in Mk-TAC
was similar to that in FVB-TAC. (F) NADPH level in Mk-sham was half that in FVBsham. TAC decreased the level ofNADPH in FVB hearts, conversely, TAC increased the
level ofNADPH in Mk hearts. Furthermore, a significant increase ofNADPH content
was observed in Mk-TAC compared to FVB-TAC. (G) NADP+ content declined in Mksham compared to FVB-sham. TAC decreased NADP+ content in both FVB and Mk
hearts. As a result, NADP+ content in Mk-TAC was significantly lower than in FVB
TAC. (H) TAC increased the ratio ofNADPH to NADP+ in Mk compared to FVB, and
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without a significant difference between Mk-sham and FVB-sham. (1) The ratio of
reduced nucleotides, NADPH plus NADH, to oxidized nucleotides, NADP+ plus NAD+
,was significantly increased in both FVB and Mk hearts after TAC, and the ratio in MkTAC was significantly greater than in FVB-TAC. No significance was found between
Mk-sham and FVB-sham. *, p<O.05, sham vs. TAC; #, p<O.05, Mk-sham vs. FVB-sham
or Mk-TAC vs. FVB-TAC by two way ANOVA analysis, n=5 for each group.
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Figure 16. Oxidative stress shown by western blot for 4HNE adducts in FVB and
Mk hearts 13 weeks :after TAC. (A) Representative western blot picture for 4HNE
adducts and GAPDH. (B) Statistical results of 4HNE adducts nonnalized to GAPDH.
TAC increased the 4HNE adducts in both FVB and Mk hearts, without significant
difference between Mk-TAC and FVB-TAC. *, p<0.05, sham vs. TAC by two way
ANOV A analysis, n=6 for each group.
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CHAPTER III
CARDIAC OVEREXPRESSION OF MITOCHONDRIAL 8-0XOGUANINE DNA
GLYCOSL YASE 1 PORTECTS AGAINST CARDIAC FIBROSIS FOLLOWING
TRANSAORTIC CONSTRICTION
INTRODUCTION

Oxidization of DNA by reactive oxygen species (ROS) can produce nucleotide
mutations potentially involved in carcinogenesis and ageing

(103). Guanine is the

nucleic acid base with the lowest oxidation potential, rendering it the most easily
oxidizable by hydroxyl radicals and singlet oxygen (80). Therefore, oxidized guanine
(7,8-dihydro-8-oxoguanine,

8-oxo-dG) is the most abundant DNA lesion following

oxidative exposure. During DNA replication, 8-oxo-dG will frequently mispair with
adenine, leading to formation of G:C to T:A transversions (11, 26, 64). DNA base
excision is a major pathway to repair oxidized nucleotides, and the enzyme 8-oxoguanine
DNA glycosylase 1 (OGGl) has a major role in the removal of 8-oxo-dG (15). For
example, OGG 1 deficiency in S. cerevisiae gives rise to a spontaneous mutator
phenotype (27); A 10 fold increase of G:C to T:A transversion frequency in DNA from
liver cells was found in homozygous OGG 1 knock out (OGG-1-)mice (46); Human OGG 1
gene mutations and polymorphisms were found to be associated with head, neck, lung
and kidey cancers (76, 77).
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Mitochondrial DNA (mtDNA) damage is more abundant and longer lasting than
nuclear DNA (nDNA) damage following exposure to oxidative stress (103, 114). A case
in point is the aging rat in which levels of 8-oxo-dG in nDNA do not change from 6 to 23
months of age while 8-oxo-dG increases 2.5 fold in mtDNA with age (32) and 8-oxo-dG
levels in mtDNA are an order of magnitude higher than in nDNA (29). One of the
reasons that mtDNA is more sensitive to ROS mediated damage than nDNA is that
mtDNA has no histone protection that can serve as a barrier against ROS. Secondly,
mitochondria are the major source for superoxide production from the electron transport
chain (ETC) thereby placing mtDNA in close proximity to ROS production. Lastly,
mitochondria have low capacity to repair mutagenesis. The level of 8-oxo-dG in mtDNA
correlates with mitochondria dysfunction in many disorders associated with oxidative
stress such as ageing and neurodegeneration (62) and levels of 8-oxo-dG are inversely
correlated to mammalian life span (7). Therefore, 8-oxo-dG in mtDNA is an important
lesion which is at least a marker and possibly a cause for development of various diseases
associated with oxidative stress.

Oxidative stress is increased in heart failure patients (37) and heart failure is
frequently associated with quantitative and qualitative defects in mtDNA (42) . In heart
failure, mitochondria produce more superoxide than normal (100). A vicious cycle can
develop for mitochondrial damage in which leakage of superoxide from the ETC
promotes mtDNA damage resulting in more ETC damage which then produces more
ROS and mtDNA damage. We hypothesized that this destructive cycle in the heart could
be disrupted by enhancing mtDNA repair via overexpression of the repair enzyme
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OGG 1.

To test this we produced transgenic mice with overexpression of OGG 1 in

cardiac mitochondria. OGG 1 transgenic mice were tested for sensitivity to cardiac injury
produced by trans aortic constriction (T AC).

MATERIALS AND METHODS

Construction of the OGGI transgenic mouse model with cardiac specific
overexpression of mitochondrial 8-oxoguanine DNA glycosylase 1

First strand OGG 1 cDNA was synthesized from human fibroblast total RNA by
superscript II and oligo dT primers (Invitrogen). The cDNA was amplified by polymerase
chain reaction ( PCR) using primers designed for the human mitochondrial isotype of
OGG 1 (12, 71)( human OGG 1-2a, sense primer with an additional Sal I restriction site,
5' -gacttagtcgaccgggagaagataagtcgcaa-3' and an antisense primers with an additional
Hind III restriction cutting site,S' -actactaagcttccagagggccacataatgtt-3 '). This produced a
1704bp fragment lacking the nuclear localization signal of exon 7. The purified OGG 1
cDNA fragment was sub cloned behind a 5.5 kb DNA fragment containing the a -myosin
heavy chain promoter (28) which produces transcription exclusively in cardiac myocytes
and in front of a 500 bp of poly (A) DNA sequence derived from the rat insulin II gene.
The sequence of the entire sub cloned OGG 1 cDNA fragment was confirmed. The
transgene was released from the plasmid by Not I digestion and microinjected into single
cell fertilized FVB mouse embryos by standard embryo microinjection procedures. All
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animal procedures conformed to the National Institutes of Health Guide for the Care and
Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and were approved by

the United State Department of Agriculture-certified University of Louisville animal care
committee. Male mice age 90-120 days were used for subsequent experiments

Transaortic constriction (TAC) surgery and Echocardiographic Assessment of
Cardiac Function

TAC surgery was performed by a modification a previously published (6) as
described in chapter I of this dissertation.

Transthoracic echocardiography of the left ventricle was performed using a 15MHz linear array transducer (15L8) interfaced with a Sequoia C512 system (Acuson) as
previously described (109) and as detailed in chapter I of this dissertation.

Mitochondrial protein and mtDNA

Mitochondria were isolated by a previously described protocol (91) with
modification. A fresh heart was cut into small pieces and homogenized by a motor
driven Teflon pestle ( Wheaton Scientific) in 5 ml of isolation buffer containing 10mM
HEPES, 200mM Malmitol, 70mM sucrose and ImM EGTA, pH 7.4. The homogenate
was centrifuged at 700g for 1Om in at 4°C. The supernatant was moved to a new tube for
centrifuging at 10000 rpm for 15min at 4°C. The pellet was collected and washed again
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with isolation buffer. The final mitochondrial pellet was used to prepare mitochondrial
DNA and mitochondrial protein. For extraction of mtDNA freshly isolated mitochondria
were lysed and extracted by Qiagen kit ( QIAprep mimiprep kit) for isolation of mtDNA.
The concentration of mtDNA was determined with a Nanodrop spectrophotometer and
the quality of mtDNA was confirmed by Sac II digestion and agarose gel electrophoresis.
Mitochondrial protein was isolated from freshly isolated mitochondria in lysis buffer
containing 2% SDS, 10% glycerol and 62.5mmollL Tris HCl ( pH 7.0), sonication and
centrifuging at 12000rpm at 4°C for 15 min. The supernatant containing mitochondrial
proteins was collected and the mitochondrial protein concentration was determined by the
Lowry method (Pierce kit). Western blots (107) of mitochondrial protein were probed
with rabbit anti hOGG 1 antibody at 1: 1000 dilution (Abeam) at 4°C over night. The
secondary antibody was incubated with the membrane for another one hour at room
temperature. Finally the antigen-antibody complexes were visualized with use of an
enhanced chemiluniescence (ECL, GE healthcare) kit. Anti-cytochrome C oxidase IV
(COX IV, Abeam) was used as loading control.

Assay of OGG 1 activity

The fresh isolated mitochondrial pellet was lysed in buffer containing 20mM
Hepes-KOH (pH 7.4), 1 mM EDTA, 1 mM DTT, 300 mM KCl, 5% glycerol, and 0.5%
Triton X-IOO on ice for lOmin. The lysate was centrifuged at 13,OOOrpm for 30min at
4°C (95). The supernatant was collected and the concentration of mitochondrial protein
was determined by the Lowry method. OGG 1 activity in mitochondria was determined
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by excising 8-oxoG from a

32 P-Iabeled

oligonucleotide substrate as described (95) with

modification. Briefly, a synthetic oligonucleotide containing an 8-oxoguanine adduct ( 5'
gaactagtgOatcccccgggctg-3', Trevigen, cat# 3850-100-01, where 0 is 8-oxoguanine) was
labeled with

y_32 p _ATP

by T4 kinase (Invitrogen) and the labeled oligonucleotide was

annealed with its complementary oligonucleotide (5' -gcagcccgggggatccactagttc-3',
Invitrogen). Unincorporated label was removed by passage over a NAP-5 column (GE
Healthcare). Fifty Ilg of mitochondrial protein was incubated with 0.1 pmol of the

32 p _

labeled duplex oligonucleotide in excision buffer (20 mM Hepes-KOH (pH 7.6), 5 mM
EDTA, 1 mM OTT, 100 mM KCI, 5% glycerol) for 3h at 37°C in a volume of 20Il!.
After incubation the reaction was terminated by addition of proteinase K (250 Ilg/ml) and
SDS (0.5%) and heating at 50°C for 15 min. Olignucleotides were precipitated with 70%
ethanol, 45mM ammonium acetate and O.Olllg/1l1 glycogen and redissolved in loading
buffer containing 70 cyo formamide, 30mM NaOH and 0.05% bromophenol blue. The
substrate and cleaved oligonucleotide product were separated on a gradient (4%-15%)
polyacrylamide gel containing 7 M urea (Invitrogen). Radioactivity in the separated DNA
bands was quantitated with a PhosphoImager and Imagequant software (Molecular
Dynamics).

Real Time Polymerase Chain Reaction ( RT -PCR)

Cardiac RNA was extracted with Trizol reagent. The total RNA was transcribed
to cDNA with Superscript II enzyme and random oligonucleotide primers (Invitrogen).
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The primers, probes and reaction buffer for RT-PCR were purchased from AB (Applied
Biosystem) including hOGGI( Hs00213454_ml), a-MHC ( Mm01313844_mH),

~

MHC( Mm00600555_ml), ANP ( MmOI255748_g1), BNP ( MmOI255770_g1),
procollagen lal(MmOI302043_g1), procollagen 3al(MmOI254476_ml), 18s RNA
(Hs99999901_s1)

and 2xMaster buffer. RT-PCR was carried out on AB 73000

thermo cycler with 35 cycles, each cycle consisted of 95°C for 15 seconds, 55°C for 15
seconds and 75°C for 30 seconds. 18sRNA was used as endogenous control for other
pnmers.

Histological experiments

Details seen described in Methods for chapter I.
Measurement of 8-oxo-dG content in mtDNA

Content of 8-oxo-dG was measured using a commercial enzyme-linked immunoassay kit ( Trevigen Inc., Gaitherburg MD) as described by Gao (23) with modification.
In brief, 0.5

~g

of sample mtDNA or 8-oxo-dG standards from 0 to 60ng/ml were mixed

with anti-8-oxo-dG antibody overnight at 4°C, the sample mtDNA and 8-oxo-dG
standards were transferred to a 96 well microplate previously coated with albumin:8-oxodG adduct and kept in the dark at room temperature for 2 hrs. The secondary antibody
coupled with peroxidase was added to each well and an incubation followed for Ih in the
dark and the plate was washed. After 6 rounds of washing, the substrate
tetramethylbenzidene was added and the reaction continued for 15 min in the dark at
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room temperature. A stop solution was used to end the reaction. The wavelength of
450nm was set to measure the absorbance of the final solution in each well. Results were
calculated according to the standard curve.

RESULTS

Characterization of mitochondrial targeted 8-oxoguanine DNA glycosylase 1
(OGGl) transgenic mice

Transgenic mIce carrymg a cardiac targeted trans gene for overexpresslOn of
human mitochondrial OGG 1 were produced as described above in the Methods section.
A total of four positive founders were obtained from 22 pups. The founder lines were
named OGGI-3, OGGl-6, OGGI-7 and OGGI-IO. Lines OGGl-3 and OGGI-IO were
fertile and passed on the transgene to approximately 50% of offspring. These lines were
tested for expression of human OGG I mRNA and mitochondrial protein and OGG I
activity. The expression of human OGG I mRNA in heart was significantly elevated
(Figure 17A, P<O.OI versus FVB control).

Human OGGI protein was markedly

increased in both transgenic lines by western blot (Figure 17B). OGG I activity measured
in extracts of cardiac mitochondria was almost two fold elevated over FVB in both
transgenic lines (Figure 17C, P<O.OI). Lines OGGI-3 and OGGI-IO had similar human
OGG I expression by all parameters, and line OGG I-I 0 was used for subsequent
experiments. To confirm OGGI activity in vivo, OGGI-IO mice were injected with
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Ilmg/kg doxorubicin or saline and 8-oxo-dG content of mtDNA was measured 48 hrs
post-injection. As shown in Figure 17D, doxorubicin increased 8-oxo-dG content in
transgenic and control mtDNA. The OGG 1 transgene produced significant reductions of
25% and 31 % in 8-oxo-dG content in saline and doxorubicin treated mice, respectively.
These results established the cardiac overexpression of active OGG 1 in transgenic mice.

Evaluation of heart size and function

Transaortic constriction (TAC) mimics human aortic stenosis with development
of pressure-overload-induced left ventricular hypertrophy. TAC or sham surgery was
performed on OGG 1 and FVB mice, and mice were sacrificed after 13 weeks. As shown
in Table 3, TAC surgery significantly increased the ratio of heart to tibia length and heart
to body weight ratio in FVB and OGG 1 mice. When compared by heart to body weight
ratio there was less hypertrophy in OGG 1 mice (P<O.05). However this was partially due
to differences in body weight. When heart weight was compared to tibia length, the
difference in hypertrophy of OGG 1 and FVB mice did not quite reach significance
(P=O.07).

Echocardiography was used to assess the effect of TAC and the OGG 1 transgene
on cardiac function. The data reported in Table 4 show that T AC mice had significantly
impaired cardiac function compared to sham mice.

This was evident by several

parameters including increased left ventricular end diastolic and systolic diameter as well
as reduced ejection fraction.

However there were no significant differences between
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FVB and OGG 1 mIce, indicating that OGG 1 overexpreSSlon did not alter cardiac
function nor protect it from the effect of TAC.

Hypertrophic mRNA markers B-MHC, a-MHC, ANP and BNP were measured to
determine whether OGG 1 could reduce the fetal pattern of RNA expression induced by
pressure overload and hypertrophy (Figure 18). These mRNAs were similar in OGG 1 and
FVB sham mice. In both OGG 1 and FVB mice, TAC produced the expected increases in
expression of B-MHC, ANP and BNP as well as the expected reduction in expression of
a-MHC. Compared to FVB TAC mice, OGGI TAC mice had 41% lower expression of
B-MHC (P<0.05), and OGGI TAC mice tended toward lower BNP expression (35%
lower than FVB TAC, P=0.12).

TAC induction of cardiac fibrosis

Semiquantative analysis showed that 13 weeks after TAC surgery fibrosis was
significantly increased in both OGGI and FVB mice (Figures 19A and 19B, P<0.05).
This analysis also showed that interstitial fibrosis staining was lower in OGG 1 TAC mice
compared to FVB TAC mice (P<0.05). The staining analysis was supported by RT-PCR
assays of cardiac collagen mRNA expression (Figures 19C and 19D). Compared to FVB
T AC mice, the expression of collagen 1a and collagen 3a mRNAs was 49% and 48%
lower in OGG 1 TAC mice, respectively (P<0.05 for both mRNAs).

8-oxo-dG content in mtDNA after TAC
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Thirteen weeks after surgery we tested whether TAC increased 8-oxo-dG content
in mtDNA and whether OGG 1 overexpression could reduce mtDNA 8-oxo-dG content
(Figure 20).

For FVB mice, TAC produced a significant 30% increase in 8-oxo-dG

(P<0.05). Overexpression of OGG 1 essentially eliminated the ability of TAC to increase
8-oxo-dG levels. In addition, OGG 1 sham mice had 25% lower 8-oxo-dG content than
FVB sham (P<0.05). These results show that OGG 1 provides protection against some
components of cardiac failure in the TAC model including reduction in fibrosis, B-MHC
expression and 8-oxo-dG content in mtDNA.

DISCUSSION

Damage to cardiac mtDNA by reactive oxygen has been proposed to contribute to
the development of heart failure (7, 42, 99). Human studies (42) and animal models (21,
52, 75, 88) have demonstrated that there is a strong association between cardiac injury
and oxidative damage to mtDNA. This relationship has been shown following numerous
different treatments including exposure to doxorubicin ((52, 88), angiotensin (81), or
isoprotemol (45), the process of ageing (14, 32), and knockout out of mitochondrial
SOD2 (63).

However no cardiac-specific models have been created to determine if

reducing mtDNA damage can protect the heart, thereby testing whether the association
between oxidative mtDNA damage and heart failure is actually a causal relationship. In
this chapter, we describe successful production of OGG 1 transgenic mice, which have
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cardiac-specific overexpression of active mitochondrial OGG 1 enzyme which catalyses
the first essential step in the repair pathway of oxidized mtDNA. OGG 1 transgenic mice
were shown to have increased hOGG 1 mRNA, elevated hOGG 1 protein and a 2 fold
increase in OGG 1 enzyme activity in mitochondria. In vivo efficacy of the trans gene was
demonstrated by reduced levels of mitochondrial 8-oxo-dG content under basal
conditions, after doxorubicin treatment and after TAC surgery. Overexpression of OGG 1
produced no measurable detrimental effects on the heart.

Thus this transgenic line

provides a suitable model for performing direct tests of a causal role for mtDNA
mutations in cardiac pathology.

The efficacy of OGG 1 overexpression in a heart failure model was tested by
challenge with TAC surgery.

Transgenic mice demonstrated essentially complete

protection from TAC induced elevation of 8-oxo-dG content, but despite this protection,
we saw little benefit of the OGG 1 transgene either to reduce cardiac hypertrophy or to
improve cardiac function measured by echocardiography 13 weeks after surgery. There
are multiple potential explanations for this lack of effect. One explanation may be that
the growth factor pathways(30) or kinase mediated actin rearrangement (50,56) activated
by mechanical stress on the heart contributing to cardiac hypertrophy and dysfunction are
not closely linked to the condition of mtDNA.

If these pathways are not linked to

mtDNA condition, then the reduction in mtDNA mutations produced by the OGG 1
trans gene cannot protect from TAC induced hypertrophy. However, the fact that OGGI
transgenic mice had reduced

~-MHC

mRNA expression after TAC suggests that mtDNA

mutations have at least a modest impact on the cardiac hypertrophy response.
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An

alternative reason for the lack of a larger OGG 1 effect may be that we did not wait long
enough after surgery. The 13 week time point after TAC may not be long enough for
sufficient mtDNA mutation to accumulate and disrupt mitochondrial function. Over a
longer period, mutated mtDNA may spread within individual myocytes from
heteroplasmy towards homoplasmy through a mechanism called" relaxed replication"
(14).

Accumulation of mtDNA mutations appears to have a high threshold before

essential mitochondrial functions are compromised: In OGG 1-1- mice elevation of 8-oxodG content in mtDNA did not produce a measurable impairment of mitochondrial
function in heart or liver (93). Potentially more time after TAC surgery or ageing studies
may be more appropriate to reveal the full benefit of the OGG 1 trans gene.

Apart from decreased mitochondrial 8-oxo-dG, the principle benefit of OGG 1
overexpression was a significant decrease in TAC induced cardiac fibrosis.

This

protection was indicated by reduced Sirius Red staining on OGG 1 cardiac sections, was
confirmed by decreased induction of collagen 1 and 3 mRNA expression in OGG 1 hearts
after TAC surgery.

Cardiac fibrosis is primarily mediated by collagen secreting

myofibroblasts (102). Myofibroblasts cannot overexpress OGG 1 due to regulation of the
transgene by the cardiomyocyte specific a-MHC promoter (2). Therefore, cardiomyocyte
overexpression of OGG 1 apparently decreased a pro-fibrotic signal that originated in
TAC stressed cardiomyocytes and acted on myofibroblasts to stimulate production of
collagen matrix.

It is surprising that the OGG 1 trans gene had only a small effect on

cardiac hypertrophy but had a large effect on fibrosis. This may imply that the profibrotic signaling process is more sensitive to mtDNA oxidation than is the hypertrophic
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response.

Alternatively, the fact that many myofibroblasts can be stimulated by a

diffusible molecule may result in amplification of the pro-fibrotic signal from just the
most damaged cardiomyocytes. The anti-fibrotic effects of the OGG 1 trans gene may be
due to protection of mtDNA resulting in production of fewer severely injured
cardiomyocytes or less pro-fibrotic signaling from these cardiomyocytes.

In summary, cardiac overexpression of mitochondrial OGG 1 reduced mtDNA
content of 8-oxo-dG in normal and stressed hearts. After TAC, protection of mtDNA
slightly reduced the hypertrophic response and clearly decreased cardiac fibrosis. These
findings support the concept that mtDNA oxidation has a causal role in cardiac damage.
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Table 3. Measurement of heart weight, body weight, tibia length and the ratios of
heart weight to body weight and to tibia length in FVB and OGGI mice 13 weeks
after TAC or sham surgery.

Parameters

FVB-sham

FVB-TAC

Heart weight (mg)

124.8±2.9

186.9±9.1

Body weight (g)

30.8±O.9

Tibia length (mm)

OGG1-sham

OGG1-TAC

128.9±3.0

a
168.8±8.0

31.8±O.7

31 .8±O.7

33.7±1.0

18.14±O.16

18.29±O.O7

18.24±O.O7

HW/BW

4.09±O.15

5.91±O.31

4.01±O.14

18.32±O.O7
ab
5.09±O.32 .

HWITL

6.88±O.14

10.22±O.50

7.07±O.16

a
9.22±O.45
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a

a

a

Legend: The notation a indicates P<O.05, FVB-sham vs. FVB-TAC or OGG I-sham vs.
OGGI-TAC. The notation b indicates P<O.05, OGGI-TAC vs. FVB-TAC by two way
ANOVA analysis, n= 11 for sham and n= 14 for TAC groups. HW/BW, the heart weight
to body weight ratio; HW/TL, the heart weight to tibia length ratio.

86

Table 4. Cardiac function measured by echocardiography in FVB and OGGl mice
13 weeks after TAC or sham surgery.

Parameter
LVEDD (mm)
LVESD(mm)
IVS (d) (mm)
IYS (s) (mm)
PWTh (d) (mm)
PWTh (s) (mm)
IYS%Th
PW%Th
IYS/PW
%FS
HR ( beats/min)

FVB-Sham
3.B1±0.OB
2.36±0.10
0.91±0.02
1.1B±0.03
O.BO±O.04
1.16±0.04
30.B7±27B
40.67±S.27
1.16±0.OS
3B.6±1.7
4B7+10

FYB-TAC
4.1S±O.OSa
2.76±0.08a
1.02±0.03a
1.29±O.03a
O.B9±O.03a
1.2S±O.02
29.26±3.S0
40.32±30B
1.13±O.03
33.B±1 .1a
S16±11
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OGG1-Sham
3.B1±0.10
2.27±O.09
0.B9±0.03
1.19±0.03
O.76±O.O3
1. 17±O.OS
33.74±2.67
4B.S1±3.31
2.2±1 .01
40.S9±1.40
S13±12

OGG1-TAC
4.03±O.08a
2.S9±O.OBa
1.0±O.02"
1.24±O.02
O.84±O.O3
1.2S±O.03
2472±2.73
49.03±4.0B
1.19±0.04
34.47±1 .068
S3S±12

Legend: Data are mean±SE. a, p<O.05, FVB sham vs. FVB TAC or OGGI sham vs.
OGG 1 TAC by two way ANOVA analysis, n= 12 for FVB sham, n= 10 for OGG 1 sham,
n=14 for FVB TAC and n=13 for OGGI TCA group. LVEDD, left ventricular end
diastolic diameter; LVESD, left ventricular end systolic diameter; lVS( d),
interventricular septum thickness at diastole; lYSes), interventricular septum thickness at
systole; PWTh(d), post wall thickness at diastole; PWTh(s), post wall thickness at
systole; lVS%Th, interventricular septum % thickening; PW% Th, posterior wall %
thickening; lVSIPW, interventricular septum to posterior wall thickness ratio; %FS,
percent fractional shortening; EF, ejection fraction; HR, heart rates.
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Figure 17. Elevation ofOGGl mRNA, protein and enzyme activity in OGGI
transgenic mice. (A) hOGG 1 mRNA level, detected by RT-PCR in cardiac RNA of
OGG 1-10 and aGG 1··3 mice was significantly increased versus FVB control ( *,
P<O.OOI vs. FVB control by one way ANOVA analysis, n=5 for each group). (B)
Western blot of expression of hOGG 1 protein in isolated mitochondria. No haGG 1 band
was detected in FVB control mice in contrast to strong bands for the two aGG 1 lines.
COX IV was used as loading control. (C) OGG I enzyme activity was measured by
cleavage of a 32p end labeled, 8-oxo-dG containing oligonucleotide substrate using 50 Ilg
of mitochondrial protein ( Probe,

32 p

end labeled oligonucleotide containing 8-oxo-dG;

Excision, excised probe; -, no protein added as blank control). The activity of OGG 1 in
the two lines was almost 2 fold higher than that of FVB control (*, p<O.O I, vs. FVB
control by one way ANOV A analysis, n=6 for each group). (D) Content of 8-oxo-dG in
mtDNA from mice 48 hr after treatment with 11 mg/kg doxorubicin. Doxorubicin
increased 8-oxo-dG content (P<0.05) in FVB and OGG 1 mice. The OGG 1 transgene
reduced 8-oxo-dG content in saline and doxorubicin treated mice (P<0.05). Statistical
analysis of 8-oxo-dG content was performed with two way ANOV A analysis, n=5 for
each group.
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Figure 18. Hypertrophic biomarkers p-MHC, a-MHC, ANP and BNP mRNA were
analyzed by RT-PCR in OGG1 and FVB hearts 13 weeks after TAC or sham
surgery. (A) B-MHC mRNA was significantly increased after TAC in both FVB and
OGGI hearts, however, the B-MHC mRNA level in OGGI TAC hearts was significantly
lower than that in FVB TAC hearts. (B) a-MHC mRNA level was significantly deceased
in both FVB and OGG 1 after T AC and no significant difference was found between FVB
and OGG 1 mice with or without TAC. (C) ANP mRNA and (D) BNP mRNA were
increased significantly after TAC compared with sham mice. No significant difference
was found between OGG 1 and FVB in sham or T AC groups. Statistical analysis was
done by two way ANOV A. *, p<O.05, Sham vs. TAC; #, p<O.05, OGG 1 TAC vs. FVB
TAC, n=5 for FVB sham, FVB TAC and OGG 1 sham, n=8 for OGG 1 TAC.
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Figure 19. Fibrosis in FVB and OGGI hearts 13 weeks after TAC. (A)
Representative sirius red staining for fibrosis in FVB and OGG 1 hearts. (B) Semi
quantitative scores for fibrosis staining performed as described in Methods by a blinded
observer. Staining of fibrosis in OGG 1 T AC hearts was significantly lower than that in
FVB TAC hearts (#, p<O.05, OGGI TAC vs. FVB TAC; *, p<O.05, Sham vs. TAC by
two way ANOVA, n=5 for each group). The expression of collagen lal mRNA (panel C)
and collagen 3al mRNA (panel D) measured by RT-PCR was significantly lower in
OGGI TAC hearts than in FVB TAC hearts (#, P<O.05, OGGI TAC

VS.

FVB TAC and

*, P<O.05, Sham VS. TAC by 2-way ANOVA, n=5 for FVB sham, FVB TAC and OGGI
sham, n=8 for OGGI TAC).
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Figure 20. Content ofS-oxo-dG content in mtDNA 13 weeks after TAC. TAC
increased 8-oxo-dG content in FVB mice (*, P<O.05 for FVB sham vs. FVB TAC).
OGG 1 lowered sham levels of 8-oxo-dG and prevented the TAC induced increase in 8oxo-dG content ( #, P<O.05 for OGG 1 sham vs. FVB sham and for OGG 1 TAC vs. FVB
TAC, all statistics by two way ANOVA, n=6 for each group).
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CHAPTER IV
OVERVIEW AND RELEVANCE OF DISSERTATION

Review of results

Hearts with either reduced or increased glycolysis exhibited several indications of
greater damage after TAC surgery. This included: More severe cardiac structural
changes including greater hypertrophy with fibrosis, greater functional changes evident
as reduced fractional shortening and increased lung weight to tibia length ratio, lower
energy reserves and higher reductive status. However, only Mb transgenic hearts with
reduced glycolysis displayed increased oxidative stress.
The OGG 1transgene which expresses the mitochondrial DNA repair enzyme 8oxoguanine DNA glycosy1ase 1 provided partial protection against the damaging effects
ofTAC surgery. This was evident as reduced fibrosis 13 weeks after TAC surgery and
reduction of 8-oxo-dG content in mtDNA.

Significance of pathology to heart failure

The results from all lines of mice implicated mitochondrial dysfunction and
oxidative stress in the pathogenesis of heart failure. Mitochondria are the major energy
source of the cell and reduced energy reserves (PCrl ATP ratio) were a characteristic of
both Mb and Mk hearts after TAC surgery. Mitochondria are also the major cellular
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source of reactive oxygen species, and the oxidative stress markers 8-oxo-dG and HNEprotein adducts were increased in both transgenic and non-transgenic TAC hearts.

Mb-

T AC hearts, in particular, appeared to have the highest level of oxidative stress as
indicated by the fact that they had the highest levels ofHNE-protein adducts. The reasons
for increased mitochondrial dysfunction in Mk- and Mb-TAC hearts may be different. In
Mb hearts, lower glycolysis could be compensated for by an increase of fatty acid
oxidation according to the theory of the Randle Cycle. Higher fatty acid oxidation
induces higher ROS production in mitochondria. In Mk mice, with higher glycolysis
mitochondrial dysfunction could be derived from glucotoxicity, possibly from more
substrates entering the AGE ( advanced glycosylation end products) and PKC ( protein
kinase C)pathways in the distal half of the glycolytic pathway. In OGG 1 mice DNA in
mitochondria was protected and OGG 1 proved to be the only trans gene that was partially
protective against heart failure. Thus Mb and Mk trans genes that increased
mitochondrial damage worsened heart failure and the OGG 1 trans gene, which protected
mitochondria reduced heart failure.

The most significant finding from Mb and Mk mice was that inhibiting the ability of
the heart to modulate glycolysis, either up or down, renders the heart more susceptible to
the stress induced by pressure overload. A possible explanation was that both Mb- and
Mk-TAC hearts showed decreased content ofNADP+, which promoted higher reductive
status. There are many enzymes which are dependent on NADP+ such as isocitrate
NADP+ dependent dehydrogenase. A decrease in NADP+ content could affect the
activities ofNADP+ -dependent enzymes and this could affect cardiac function. NADP+
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content is associated with calcium signaling, and abnormal NADP+ content probably
causes abnormal calcium signaling (47), which could cause cardiac hypertrophy (78).
Regardless of the specific mechanism, neither Mk nor Mb induced cardiac damage unless
the heart was exposed to pressure overload. This indicates that under normal conditions
the heart is able to compensate for significant changes in metabolism.

Clinical relevance
Ultimately the aim of this work is to better understand and thereby enhance our
ability to treat patients with cardiac dysfunction. A beneficial aspect of higher glycolysis
in Mk-TAC hearts was increased content ofNADPH, which is important as an
antioxidant agent. However, the higher NADPH content could not prevent severer
cardiac structural and functional changes induced by TAC. This suggests that antioxidant drugs alone may not be able to completely protect the heart. The data from the
OGG 1 transgenic mice suggest that oxidation of mtDNA could result in higher fibrosis,
which is associated with cardiac remodeling, thus anti oxidant drugs that provide
protection ofmtDNA against ROS may be useful for the prevention or treatment of heart
failure.
Several candidate drugs are available or in development to treat angina, ischemic
heart diseases, heart failure and diabetic heart diseases by changing metabolism through
shifting fatty acid oxidation to glucose oxidation (74). These include trimetazidine,
ranolazine, perhexiline and etomoxir. Trimetazidine, an anti angina agent, decreases
fatty acid oxidation by inhibiting 3-ketoacyl coenzyme A thiolase, thereby relieving
inhibition of pyruvate dehydrogenase activity and correspondingly increasing glucose
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oxidation (74). This anti-angina agent can relieve symptoms due to oxygen sparing
effects and reduced intracellular acidosis and calcium overload, probably through
coupling glycolysis and glucose oxidation. However, according to our results,
permanently manipulating cardiac metabolism, either by increasing or decreasing
glycolysis, is detrimental and increases heart failure. The same concerns apply to each of
the candidate drugs that are porposed to benefit the heart by changing cardiac
metabolism. Therefore great care should be taken before long term application of these
drugs to heart failure patients.

Future studies
Future studies are needed to understand the specific changes in mitochondrial
function in Mk, Mb and OGG hearts. It should be determined whether mitochondrial
respiration efficiency is altered, whether changes are present in the electron transport
chain and it should be tested if the amounts of superoxide produced is increased. We
should also test whether these transgenes produce similar changes in heart dysfunction
using different models of heart failure or damage. These models could include chronic
stress in the heart with known hypertrophic agents, such as angiotensin II and
phenylephrine. The effects of altering glycloysis may be especially relevant to diabetic
cardiomyopathy in which changes in fuel use are likely to be a major component of the
cardiac pathology. Since human ageing is associated with mutations of mtDNA the
OGG I gene would be especially useful for studying cardiac aging. The OGG 1 trans gene
had lower base line of oxidized guanine, thus the OGG 1 trans gene would be predicted to
decrease the detrimental effects of aging on cardiac function.
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